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Abstract 
Colorectal Cancer (CRC) is the first major common cancer among men in Gaza Strip (GS) 
and it is considered the second common cancer after breast cancer for both sexes 
combined. Survival analysis for CRC cases is essential for monitoring and evaluation of 
health care system effectiveness in managing and fighting CRC. This non-concurrent 
prospective study was conducted to analyze the survival data for CRC cases who were 
diagnosed in the period 2008-2010, and to give estimates about overall survival rate, 
disease free survival rate, progression free survival. Beside exploring main factors may 
affect on survival rates for CRC in GS. 
After some cases were excluded due to various causes, 207 cases were eligible for this 
study. The main source for data was the medical records for the cases, and data analysis 
was conducted by using SPSS program version 22. Kaplan-Meier method was used to 
provide overall survival estimates, survival estimates adjusted to selected prognostic 
factors and survival curves for subgroups, while the log rank test was used to assess 
survival differences between the subgroups. Cox regression survival analysis was used to 
examine the independent effect of study variables on survival data and to estimate the 
hazard ratio. Statistical significance was defined as P <0.05. The study findings showed 
that CRC incidence rate in Gaza Strip (GS) was 14/100000 in the study period (2008-
2010).  
Findings regarding socio-demographic characteristics of study population revealed that 
the mean of age at diagnosis for cases was 59.6 years, incidence rate among male is 
slightly higher than female (Male:54.6%, female:45.6%), 16.4% of cases were unmarried 
at time of diagnosis, while data about education level and work were missed from the 
majority of medical records. All cases presented with signs and symptoms at time of 
diagnosis. The common signs and symptoms were bleeding per rectum and abdominal pain 
63.3%, 35.3% from all cases respectively. The most common histological type was Non-
mucinous adenocarcinomas which accounted 86.7%. More than two third of cases were 
diagnosed with low grade tumor (grades 1, 2), while more than the half of patients (61.6%) 
were diagnosed with advanced stages (III, IV). Left-sided colon is the most common site 
for developing CRC with 52.3% of all cases. It followed with rectal cancer with 25.9%, 
while right-sided colon accounted only 21.9%. The study revealed that 5-year observed 
overall survival rate, disease free survival rate, and progression free survival rate 
probabilities to be  45%, 59% and 19% respectively.  
According univariate analysis (log rank test) survival rate was significantly affected by co-
morbidity status (P-value: 0.040), smoking (P-value: 0.002), stage at diagnosis (P-value< 
0.001), tumor grade (P-value=0.41), tumor site (P-value=0.004), and treatment type (P-
value=0.001). While the multivariate analysis (Cox regression) showed that only three 
prognostic factors had statically significant effect which were stage at diagnosis (P-
value<0.001, 95%CI 2.673-9.034), Co-morbidity status (P-value=0.031, 95%CI, 0.434-
0.962) and tumor site (P-value0.018, 95%CI, 0.373-0.912). Factors such as main treating 
hospital, diagnostic delay, treatment delay and place, sites of distant metastasis, gender, 
age, residency, or family history of cancer were found to be without statically significant 
effect on survival data for CRC cases in GS. 
According the current study results, 5-years survival estimates in GS is poorer than the 
estimates in the developed countries, which were between 60-70% there. However, they 
are in line with most the estimates in the Arabic countries where the survival rates between 
30-50%.  
v 
 
The study concluded that the absence of a national CRC screening program, poor public 
awareness and official attention, and absences/shortage of many cancer services in GS 
may be the main causes for poor CRC survival estimates. Decreasing gaps in the last three 
issues may contribute to enhance the survival data, prevent premature deaths, and promote 
the quality of life for CRC cases in GS. 
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Chapter (1): Introduction 
1.1 Background 
Cancer is a major cause of morbidity and mortality worldwide, and its burden rises over 
recent decades. According to International Agency for Research on Cancer-IARC (2014), 
Colorectal Cancer (CRC) is one of the most cancer affects both sexes worldwide and it 
ranks the second most common for female cancer and third male cancer representing about 
10% of global cancer incidence in 2012. Even though CRC is more common in developed 
countries and relates with modern civilization, its incidence is rapidly increase in many 
countries around the world especially in Asia and Eastern Europe, which reflecting 
increasing the load of risk factors related to CRC such as obesity, smoking, diet habits and 
other factors associated with  westernization culture (American Cancer Society-ACS, 
2015a). In the last 10 years, CRC incidence rates in many Arabic countries have been 
increasing, even though its figures still lower than the figures in the developed countries 
(Arafa & Farhat, 2015). On the other hand, many recent studies showed remarkable 
improvement in CRC survival rate in developed countries which indicated that determining 
the prognostic factors and modified it will lead to improve overall survival rate from CRC 
(Zare-Bandamiri et al., 2016).  
Palestine as many developing countries is experiencing an epidemiological transition 
where the burden of the chronic diseases become the greatest. Cancer diseases are 
considered the second most common chronic diseases after cardiovascular diseases 
(Mosleh, 2016). Also cancer is considered a public health problem which affecting both 
sexes with growing incidence rates for certain cancer types such as breast cancer and CRC 
and the Gaza Strip (GS) in last few years have been experiencing clear steadily increasing 
trend in cancer diseases incidence. Ministry of Health (MOH) records mentioned that CRC 
is the first common cancer among males in GG, and the second among both sexes 
combined (MOH, 2015a). Another MOH reports shows that cancer diseases as overall are 
the second leading cause of death after cardiovascular diseases in GS (MOH, 2014).  
Palestine as many developing and less developed countries lacks to population based 
survival studies for cancer diseases, and to the best of the researcher knowledge, there was 
no any studies for CRC survival analysis were done. Survival rate is a useful measure for 
monitoring the effectiveness of health care management of CRC (Foot and Harrison, 
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2011). Also survival analysis is main indicator for the efficacy of heath care system 
delivery. Survival of CRC is affected by many factors such as patient socio- demographic 
 characteristics, tumor histological type, the stage at diagnosed, and health management 
factors. Worldwide, there are large differences in survival rates between economically 
developed and developing countries. Also 5-years survival rates for CRC cases were 
diagnosed in early stage exceeds 90% compared with 10% for metastatic cases (Waghray 
et al., 2016). In this study the researcher will give the fist estimation of survival statistics 
for CRC patients in GS. Beside the study will focus on the main determinants which may 
affect on survival rate among CRC cases in GS and determined overall survival rate and 
adjusted survival rate to selected prognostic factors such as stage at diagnosis and 
metastasis status. Ultimately the study results will provide a baseline of useful information 
CRC prognosis which helps in detecting gaps in management of CRC to enhance survival 
of CRC and prevent premature deaths which are attributable to it. Beside that identifying 
of main factors associated with survival of CRC will help policymakers, health planners 
and physicians to develop effective strategies and plans to fight CRC and promote survival 
rate by decreasing suspected gaps in main factors associated with CRC survival rate in the 
Gaza Strip. 
 
1.2 Research problem 
 
Recent MOH reports showed that the CRC is the first major common cancer among men in 
GS and it is considered the second major common cancer after Breast cancer for both sexes 
combined (MOH, 2015a). Furthermore cancer diseases as overall are the second leading 
cause of death in GS after heart diseases (MOH, 2014). Current situation of cancer 
management in Palestine is complicated from one hand cancer incidence in increasing 
trend, and from the other hand many of cancer services is poor or absent such as 
radiotherapy, PET CT, special palliative therapy especially in Gaza Strip, So that MOH 
referred routinely many cases to be treated abroad (in East Jerusalem, West Bank, and 
others). As overall referral for treating cancer only (rather than diagnostic procedures) 
ranks on the top of the causes for referral abroad which increases the load on health care 
system  in Palestine (MOH, 2016a). Notwithstanding the foregoing and to the best of 
researcher knowledge survival statistics for CRC patients in GS are not available.  
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The survival rates and mortality rates are essential for evaluation the effectiveness of 
health care system in managing CRC and adjusted survival rates according selected 
prognostic factors such as stage at diagnosis, tumor site, socio-demographic factors, and 
others are used  as evaluation tools for how these factor affecting survival rate for CRC  
patients in GS.  
This currents study will be the first study to estimate CRC survival rate in GS and defining 
main factors affecting its prognosis, so it will give the baseline of the survival data about 
CRC in GS which may is used for future improvement plans.  
 
1.3 Justification of the study 
 
Survival analysis is very important tool for monitoring the effectiveness of health care 
systems, and survival rate is considered main indicator which reflect many factors both in 
population and health care system delivery. It can used to evaluate the effectiveness of 
screening program and detecting cancer as early as possible, the effect and success of 
treatment protocols, and also it used as comparator indicator among different population 
(Foot et al., 2011). 5-year survival rate is used widely over the world to quantify the 
burden of CRC mortality. In Gaza Governorates (GG), even though MOH reports in GS is 
showing increasing trend in CRC incidence, the population-based survival analysis of CRC 
cases in GG is absent. And to the best of researcher knowledge survival statistics regarding 
CRC in the Gaza strip is unavailable. So it will be worth and rationale to conduct study to 
provide estimation of CRC statistics in GS due to survival statistics significance. 
Accordingly this study will gain more importance because it will be the first study will 
examine the survival rates and explore the main factors correlated with CRC in GG. Study 
results will give a baseline of information and opportunities for health care system 
stakeholders to understand and address inequalities in the management of CRC and define 
areas for future possible improvement. This will contribute to prevent premature deaths of 
CRC cases and improving the quality of life for CRC patients in GS. 
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1.4 Study objectives 
1.4.1 General objective 
To explore the observed survival rate for colorectal cancer cases, and investigate main 
factors may associated with Colorectal Cancer (CRC) survival in GS at the period between 
(2008- 2010). 
 
1.4.2 Specific objectives of the study 
1. To determine the overall 5-years survival rate for colorectal cancer cases in GS. 
2. To identify adjusted survival rates according to certain prognostic factors such as 
stage at 
diagnosis, and histological type of tumor. 
3. To assess the impact of socio-demographic factors such as gender, age at 
diagnosis, and 
residency on survival rate . 
4. To investigate how healthcare related factors such as delay in diagnosis, treatment 
type and delay in treatment affect on survival rate of CRC. 
5. To develop recommendations that may improve the survival rates and prevent 
premature deaths from CRC in GS. 
1.5 Research question 
1. What is the overall five years survival rate for CRC cases in GS? 
2. What are main factors correlate with CRC survival rate in GS? 
3. How stage at diagnosis affects on the progression of CRC? 
4. Is survival rate for CRC cases affected by socio-demographic characteristics of the 
cases? 
5. Are there survival differences between male and female CRC patients in GS? 
6. Is diagnostic delay affect on the survival rate for CRC cases? 
7. How CRC progression affected by treatment delay? 
8. Which are treatment issues related with survival rates for CRC cases in GS? 
9. What is overall survival rate for non-metastatic and metastatic cases? 
10. hat is disease free survival rate for non-metastatic cases and progression free 
survival 
rate for metastatic cases? 
11. Which are main suggestions to improve the survival rates for CRC cases? 
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1.6 Study context 
1.6.1 Gaza Strip overview 
 
The GS is a small piece of land located in the southern area of State of Palestine (SoP). 
SoP is a small country with about 27.009 km2. It is located in the west of Asia continent, 
and in the east of the Mediterranean Sea (Annex 1). It is boarded from the north by 
Lebanon and Syria, from south by Egypt and the Gulf of Aqaba, and from east by Jordan. 
GS is divided into five governorates: North Gaza, Gaza, mid zone, Khan Younis, and 
Rafah (Palestinian Central Bureau of Statistics-PCBS, 2015) (Annex 2). 
The total population in Gaza Strip governorates was around 1.82 million in mid-2015, 
where is considered from the most crowded areas over the world with more than 8,328 
individual per square kilometer. Population in GS is characterized by youth bulge with 
55% from total population are less than eighteen years old. Average family size in GS is 
5.8 individual, 50.8% from total population in GS are male, while 49.2% are female, and 
life expectancy for males and females is 71.2 and 74.1 respectively. The unemployment 
rate in GS increases from 37.8% in 2010 to 43.9% in 2014, while the poverty rate was 38% 
in 2010 (MOH, 2015b).  
The World Bank classified the socioeconomic status of GS and WB at the low-middle-
income level. GS has sharp economics deterioration in recent years mainly due the military 
siege and isolation of population (Abed, 2007). According to MOH (2015c) the total 
number of chronic diseases patients in GS in 2014 was 116762 patients. Hypertension 
disease accounts 33.4% of total number of chronic disease which considered the most 
common chronic diseases followed by Diabetes mellitus disease, while cancer diseases 
accounts 3.3% ranking the fifth in term of number of patients. 
1.6.2 Health care system 
 
Palestinian health care system is a complex system due to the health services delivery in 
Palestine consists from multi-major health care providers: Ministry of Health (MOH), 
United Nation Relief and Work Agency for the Refugee of Palestine in the Near East 
(UNRWA), Non- Governmental Organizations (NGOs) and profit private sector. MOH is 
considered the main health care provider and according to the Palestinian Public Health 
Law, the main roles and tasks of the MOH are providing, regulating and supervising the 
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delivery of health care in Palestine. Also, MOH is responsible about the planning the 
health care services in coordination with different stakeholders, enhancing health 
promotion to improve the health status, developing human resources in health sector, 
managing and disseminating health information, and others (MOH, 2016a).  
In GS, the Latest MOH report regarding the hospitals in GS in year 2015 which is 
published in 2016 shows that there is thirty hospitals with 2816 beds are distributed as the 
follow: 2242 hospital beds in the governmental hospitals and 574 beds in non-
governmental sector (MOH, 2016c).  
European Gaza Hospital (EGH) and Al-Shifa hospital are two main hospitals provide adult 
cancer services in GS. Regarding the diagnostic tests and procedures for CRC, they are 
available in CS which include the endoscopic examinations, Computed Tomography (CT), 
Magnetic Resonance Imaging (MRI) and others except Positron Emission Tomography–
Computed Tomography (PET CT) still unavailable in GS (Thabet, 2017). The same source 
added that the cancer therapy in GS is facing many difficulties and challenges such as 
shortage of supply the systemic therapy, unavailability of some important drugs, shortage 
of training courses for the oncology team, beside the overcrowding of cancer patients in 
the oncology department. These difficulties long the patient waiting list for chemotherapy 
which contributes to delay in receiving the chemotherapy also delay in the referral abroad.  
 
1.6.4 Al-Shifa Hospital 
 
Al-Shifa hospital was established on 1946 and developed over years, its buildings over 
45.000sq.m and the total number of beds 696 beds. In the fact, Al-Shifa is medical 
complex that includes three hospitals: Surgery hospital, internal medicine hospital and 
women's and obstetrics hospital. The hospital has been the key center for the Palestinian 
population living in Gaza Governorates. It locates in the west part of Gaza city, in the 
North Rimal district. 
Oncology department at Al Shifa hospital was constructed since 1984 with one big room 
and over years developing and give health services to patients with hem-oncology diseases 
from age 12 years. It was built at 1992 and rebuilding at 2001, it consists of five normal 
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rooms with fifteen beds and four isolated rooms with one bed for each isolated room (El 
Shifa Hospital records, 2013). 
1.6.5 European Gaza Hospital 
 
European Gaza Hospital (EGH) was built in 1993 in Khan Yonis governorates at the south 
of the GS. At the beginning, the management of EGH was delivered by European Union, 
and then on 15 October 2000 the management authority was transferred to the Palestinian 
staff.  
EGH is considered as referral center and providing secondary care for Rafah and Khan 
Yonis governorates. The EGH involves adult medical-surgical services, cardiac 
catheterization, cardiology, outpatient clinics, medical and surgical pediatrics, pediatric 
intensive care unit, radiology, and adult oncology. The EGH consists of 245 beds and 
includes computerized network system with quality care for patients and the hospital offers 
special health services to people from all GG (EGH records, 2013). 
 
1.6.6 Cancer registry in Gaza governorates 
 
Cancer registry is defined as an information system designed for the collection, storage, 
management, and analysis of data on persons with cancer, usually covering a hospital or 
group of hospitals. In Palestine, MOH with cooperation of Middle East Council of 
Churches established the Palestinian cancer Registry (PCR) which considered a population 
based registry in 1996, and started its regular work in 1998. Defining the burden of the 
cancer problem and pattern of its occurrence are the main purpose of the PCR. Since lunch 
of PRC the registrations process in PCR centers have been affected by unrest political 
circumstances in the Palestinian regions and due to Israeli measures, which divided 
Northern governorates (West Bank) into 43 separate areas, and continuity of Israeli siege 
for Gaza strip. Beside other problem which include internal conflicts and political and 
geographical separation between GS and WB (MOH, 2002). The registry process in Gaza 
governorates extends from 1995 until present with the registry including all cancer cases 
from its different sources. Cancer registry collect data from five main sources which 
include; The first source is governmental hospital which provide cancer services, the 
second is governmental and private histopathological centers, the third governmental, 
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UNRWA, and private radiology centers, the fourth is treatment abroad referral records, 
finally the death certificates (MOH, 2015a). 
 
1.7 Operational definition 
Survival analysis 
Survival analysis is a set of methods for analyzing data where the outcome variable is the 
time until the occurrence of an event of interest. The event can be death, occurrence of 
disease, re-occurrence of disease and others.  
Survival rate 
"The percentage of people in a study or treatment group who are still alive for a certain 
period of time after they were diagnosed with or started treatment for a disease, such as 
cancer. The survival rate is often stated as a five-year survival rate, which is the percentage 
of people in a study or treatment group who are alive five years after their diagnosis or the 
start of treatment. Also called overall survival rate" (NCI, 2016a). 
Diseases free survival rate (DFS) 
“The length of time after primary treatment for a cancer ends that the patient survives 
without any signs or symptoms of that cancer” (NCI, 2016b). 
 
Progression free survival rate (PFS) 
"The length of time during and after the treatment of a disease, such as cancer which a 
patient lives with the disease but it does not get worse. In a clinical trial, measuring the 
progression-free survival is one way to see how well a new treatment works "(NCI, 
2016c). 
The smoker 
The patient is defined as smoker if she/he smoked any kind of smoking (Cigarette, hubble 
bubble…) at any time of his life, while he is defined as non-smoker if he does not smoke 
any kind of smoking at any time of his life. The smoking is suspected to have negative 
effect on CRC prognosis and the survival rates. 
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Obesity status 
In current study, the patient is defined as obese if the Body Mass Index (BMI) more than 
25 kg/m2, and with normal weight if the BMI less than 25 kg/m2   
 
Interval to diagnosis and diagnostic delay 
Interval to diagnosis is defined as the period between first time for appearance of signs and 
symptoms to date of confirmed diagnosis. The patient is defined to have diagnostic delay if 
the interval to diagnosis exceeds three months.   
 
Interval to treatment and treatment delay 
Interval to treatment is defined as the time between date of pathological diagnosis, usually 
via open biopsy, and the date of initial therapy, either surgical or systemic. Treatment 
delay is divided to two construct: The surgical intervention delay which occurs if the 
interval to the surgery exceeds fourteen days from date of confirmed diagnosis, while the 
chemotherapy delay is defined as waiting time for chemotherapy exceeds three months 
after patient have the surgery. 
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Chapter (2) Literature review2.1Conceptual Frame work 
 
After the literature was reviewed by the researcher thoroughly with help from the 
supervisor, he grouped the main factors that may associated with CRC survival in three 
groups which are considered the main blocks for this current study (figure2.1). The three 
groups include patient related factors, tumor related factors, and healthcare related factors. 
Figure (2.1) Conceptual Framework - Self Developed 
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2.1.1 Patient Related Factors 
Patient related factors include the following factors (Age at diagnosis, Gender, Work, 
Education, Material status, Residency, Co-morbidity, and Health-related behaviors 
(smoking, diet, obesity, physical inactivity). The researcher studied how these factors 
which related to patient himself affect on CRC prognosis and the survival rates. Each 
variable will be explained in the following paragraphs.  
 Age  
Age for study population was obtained at date of confirmed diagnosis by biopsy 
(histopathological study report). Age at diagnosis is suspected to have an effect on 
CRC prognosis and survival rates. 
 
 Gender 
The gender is defined as factor in the current study to explore the impact of cases 
gender on survival rate, and to examine if there are differences in survival rates 
between female and male CRC cases. 
 
 Work 
The patients work included in this study due to it is expected to affect on CRC 
prognosis positively or negatively.      
                      
 Education 
Cases’ medical records were assessed for information about education level for 
cases. As data availability about education level of cases, analysis was done to 
define impact of education level on survival form CRC. 
 
 Material status 
Unmarried and married status of the study cases at date of confirmed diagnosis and 
journey of treatment were obtained to investigate the suspected relationship 
between marital status at diagnosis and prognosis of CRC. 
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 Residency 
The place of residency for cases was studied to assess if there are survival variance 
based on the area of residency. There five governorates in GS which are (North 
Gaza, Gaza, Mid-Zone, Khan Youis, and Rafah), so the study population are 
classified to five groups according area of residency (governorate).  
 
 Co-morbidity 
The presence of other diseases in addition to CRC correlates with human ability to 
survive from CRC. Dramatically the other diseases may deplete body ability to 
fight CRC. In this study two main chronic diseases are studied which combine with 
CRC (diabetes mellitus (DM) and hypertension (HTN)). These diseases are 
suspected to have negative effect on CRC prognosis and the survival rates. 
 
 Health-related behaviors 
Information about health related behaviors were obtained from available data in the 
patient’s medical records. Health related behaviors include: smoking, diet regime, 
obesity, and physical activity status of cases at time of confirmed diagnosis of 
CRC. These variables are studied to define the effect of these behaviors on CRC 
prognosis and survival rates. 
The patient is defined as smoker if he smoked any kind of smoking (Cigarette, 
hubble bubble…) at any time of his life, while he is defined as non smoker if he did 
not smoke any kind of smoking at any time of his life. The smoking is suspected to 
have negative effect on CRC prognosis and the survival rates. 
About diet, available information in the patients' medical records was collected. 
Even though the Gazans have same race, same culture, and same dietary norms, 
some difference may be presented between poor and rich patients especially about 
the food quality and diversity.  
While regarding physical activity, also available information about physical activity 
status at time of diagnosis were collected and sorted into three categories (physical 
active, moderate, and poor activity). 
Height and weight for the study cases were obtained from the medical records to 
calculate the Body Mass Index (BMI) in order to define the obesity status. The 
obesity is defined as a factor may an effect on the survival rates for CRC cases.   
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2.1.2 Tumor Related Factors 
Tumor related factors include histological type, tumor grade, stage at diagnosis, and tumor            
site. The following paragraphs will describe each variable. 
 
 Histological type 
There are different histological types of CRC. The most common type is 
adenocarcinoma and the other less occurred type is mucinous adenocarcinomas. In 
this study, two main histological types are studied which are non-mucinous 
adenocarcinomas and mucinous adenocarcinoma as general.  
 
 Tumor Grade 
Based on CRC classification of WHO and American Cancer Society (ACS), there 
are four grades of colorectal carcinomas (grade 1 (G1), grade 2 (G2), grade 3 (G3), 
and grade 4 (G4)). G1 for cancer looks much like normal colorectal tissue also G1 
is called well differentiated, G2 is intermediate grade which is called moderately 
differentiated, G3 is high grade which is called poorly differentiated, while G4 for 
cancer looks very abnormal which is called poorly undifferentiated, anaplastic 
(Fritz et al., 2000; ACS, 2015b). 
 
 Stage at diagnosis 
Four main stages derived from TNM classification system of CRC are (stage I, 
stage II, stage III, and stage IV). Stage I is  described when the tumor is localized 
on the lining of the colon, stage II when The tumor grows into the outer lining of 
the colon or surrounding tissue, stage III when metastasis to the lymph nodes is 
present, while stage IV when metastasis to distant organs in the body is present. 
Stage at diagnosis was determined from data at the medical records where the data 
were analyzed to see impact of stage at diagnosis on survival from CRC.  
Stage at diagnosis is suspected to be main variable affects on CRC prognosis and 
the survival rates.  
 
  
14 
 
 Tumor site 
In this study the cases are divided to three groups according tumor site (patients 
with right-sided tumors, left-sided tumors, and rectum tumors), in order to 
investigate the relationship between tumor site and the survival rates from CRC.  
 
2.1.3 Healthcare Related Factors 
Healthcare related factors include two main groups of factors (Diagnostic related factors 
and treatment related factors). The following paragraphs will describe each factor from the 
two groups.  
 
2.1.3.1 Diagnostic related factors 
 Diagnostic delay: Is the condition if the interval to confirmed diagnosis exceeds 
three months from date of signs and symptoms started. Diagnostic delay is defined 
as prognostic factor in this study and it is suspected to effect negatively on CRC 
prognosis. 
 Signs and symptoms: There are many signs and symptoms related to CRC directly 
or indirectly. The signs and symptoms which are studied in this current study 
include bleeding per rectum, constipation, abdominal pain, intestinal obstruction, 
and diarrhea.  
   
2.1.3.2 Treatment related factors 
Treatment related factors include treatment delay, treatment type, and treatment location. 
Each factor is described as the following.  
 Treatment delay: The patient is defined to have treatment delay if the time from 
confirmed diagnosis to the surgery exceeds 31 days in this condition is called 
surgery delay or the time from the surgery to the chemotherapy exceeds 3 months 
in this condition is called chemotherapy delay. The treatment delay is defined as 
factors may affect on CRC prognosis negatively.  
 Treatment types: Include four main types of treatment are provided to CRC cases 
which are surgical intervention, chemotherapy, radiotherapy, and palliative care. 
 Treatment place: CRC cases in the GS are treated in different places, and the main 
places are GS, WB, East Jerusalem, Israel, and Egypt. Treatment place is defined as 
a variable may affect on the survival rates from CRC.  
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2.1.4 Overall Survival 
 
This is the percentage of cases with CRC who have not died from any cause during a 
certain period of time after diagnosis. Five years overall survival rate are calculated for all 
the study cases. It will be the first estimation of five years survival rate for CRC cases in 
GS. 
2.1.5 Non-Metastatic Cases 
Non-Metastatic Cases are defined as CRC cases that are diagnosed with stage I, stage II, or 
stage III at time of diagnosis without distant metastasis to other organs. The overall 
survival rate and disease free survival rate are conducted for this group to see the treatment 
benefits and distant metastasis effects on the overall survival rate. 
2.1.6 Disease free survival (DFS) rate  
The length of time after primary treatment for a cancer ends that the patient survives 
without any signs or symptoms of that cancer. In this study DFS is calculated by 
determining date of surgery (Surgical removal of the tumor) and date of CRC recurrence.   
 
2.1.7 Metastatic Cases 
Metastatic cases are defined as CRC cases who are diagnosed with stage IV at time of 
diagnosis with distant metastasis to other organs such as liver, lung, brain, bone and others. 
 
2.1.8 Progression free survival rate 
The length of time during and after the treatment of metastatic CRC which a patient lives 
with the CRC but it does not get worse. It is calculated by determining date of treatment 
start and date of disease progression. It used to examine how far the treatment does well.   
 
2.2  Literature review  
2.2.1 Anatomy of the colon and the rectum 
 The colon and the rectum are parts of the digestive system, which they make up the large 
intestine, annex (3). The colorectum starts from the terminal ileum to the anal canal, and it 
is divided respectively as the follow: Cecum, appendix, ascending colon, hepatic flexure, 
transverse colon, splenic flexure, descending colon, sigmoid colon, recto-sigmoid segment, 
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rectum, and anal canal. As general, the colorectum is divided into three main parts, the 
right colon, the left colon, and the rectum. The right colon include cecum, appendix, 
ascending colon, hepatic flexure, and the right half of transverse colon, while the left colon 
includes left part of transverse colon, splenic flexure, descending colon, sigmoid colon, and 
the recto-sigmoid segment is a shared part between the left colon and the rectum, whereas 
the rectum include the anal canal and the anus (NCI, 2016d; ACS, 2015b). 
  
2.2.2 Colorectal cancer definition 
CRC refereed to tumors which start in the colon or the rectum, and they usually grouped 
together because they have many similar features. Mostly CRC begins as polyps, but not 
all polyps change to cancer. There are many types of polyps, the two main types are 
adenomatous polyps which sometimes change to cancer, so they are called a pre-cancerous 
condition, and the hyperplastic polyps and inflammatory polyps which are the common 
and rarely change to cancer (ACS, 2015b). The most common origin of CRC is 
adenomatous polyp, hence the majority of CRC are adenocarcinomas, which constitute 
about 96% from all types. The others rare types include lymphoma, carcinoid tumors, 
melanoma and sarcomas (Al Nsour, 2014). 
2.2.3 Clinical manifestation of colorectal cancer 
According to ACS (2015b), CRC patients sometimes do not complain clearly from 
symptoms and signs related to CRC especially in the early stages. Major patients with 
early stage have not symptoms of CRC, and they are diagnosed by screening. Recent 
studies show that more than 70% up to 90% of CRC cases presented at onset of symptoms 
at time of diagnosis, hence mostly of CRC cases are diagnosed at advanced stages. The 
main signs and symptoms of CRC due to local tumor include blood per rectum, abdominal 
pain, anemia, change in bowel movements, intestinal obstruction, and others, while the 
patients with metastatic CRC are presented with extra symptoms such as pain at upper 
quadrant of abdomen, abdominal distention, early satiety, supraclavicular adenopathy, or 
periumbilical nodules (Macrae et al., 2016). 
2.2.4 Risk factors for colorectal cancer 
The risk factors for CRC can be divided into non modifiable risk factors and modifiable 
risk factors. The non-modifiable risk factors include inherited genetic mutations such as 
Lynch syndrome (hereditary non-polyposis CRC and familial adenomatous polyposis), 
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personal or family history of CRC, personal history of chronic inflammatory bowel 
disease, and also the risk for developing CRC increase with age. While the modifiable risk 
factors for CRC include obesity, physical inactivity, a diet high in red or processed meat, 
heavy alcohol consumption, and smoking (ACS, 2011). 
2.2.5 Staging of colorectal cancer 
 
The first staging system for CRC was developed by Cuthbert Dukes In 1932, and through 
years dukes staging system was been modified to have more prognostic factors (Fisher, 
1989). While the most common used staging system for CRC was developed by American 
Joint Committee on Cancer (AJCC) which called the Tumor, Node, and Metastasis (TNM) 
staging system. T is refereed to primary tumor, N is refereed to lymph node, and metastasis 
is denoted by M. These three letters T, N, and M are followed by number to give further 
information. Usually the stage of cancer is quoted with Latin number as  I, II, III, IV 
derived from the TNM system value, where the higher number indicate more advance 
stage (Al Nsour, 2014). 
2.2.6 Colorectal cancer grades 
 
The grade of cancer describes the microscopic features of tumor, how it looks like normal 
tissue. 
The scale used for grading CRC is from 1 to 4. The Grade 1 (G1) for cancer looks much 
like the normal colorectal tissue, and the Grade 4 (G4) for cancer looks very abnormal. 
Grades 2 and 3 (G2 and G3) for vague it fall somewhere in between G1 and G4 (ACS, 
2015b). 
Another classification of CRC grades based on International Classification of Diseases- 
Oncology ICD-O third edition as the follow: Well differentiated = G1, moderately 
differentiated = G2, poorly differentiated = G3, and undifferentiated anaplastic = G4). 
 
2.2.7 Colorectal cancer screening 
 
According Center for Disease Control and Prevention CDC (2016), the screening test is 
done to assess the disease in clients without any signs or symptoms related to CRC. 
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Discovering CRC at early stage is crucial in decreasing mortality rate and increase survival 
rate (Al Nsour, 2014).  
According ACS (2016a) the 5-year survival rate is about 90% if CRC is found at early 
stage, but unfortunately only 40 % of all CRC cases are found at this early stage. The same 
source added that only half of people who need CRC screening test, get the needed tests 
and it is explained that by things such as lack of public and health care providers awareness 
of screening options, the screening tests costs, and health insurance coverage issues. The 
American guidelines for CRC screening recommend for men and women to begin the 
screening tests at age 50. They recommend three main screening tests which the individual 
at least should to do one of them. The screening tests are colonoscopy (once every 10 
years), high-sensitivity fecal occult blood test, and flexible sigmoidoscopy (every 5 years).  
 
2.2.8 Colorectal cancer Diagnosis 
 
According to Canadian Cancer Society (2016), the main diagnostic tests and procedures 
are used for CRC diagnosis are health history and physical exam, complete blood count 
(CBC), blood chemistry tests, stool tests, double-contrast barium enema, sigmoidoscopy, 
colonoscopy, cell and tissue studies, digital rectal exam (DRE), CT scan, PET CT, MRI, 
and chest x-ray. 
 
2.2.9 Treatment 
CRC treatment depends mainly on stage and grade of CRC at diagnosis. Treatment options 
for CRC include the surgery which is considered the main treatment for CRC without 
metastasis. The permanent colostomy (creation of an abdominal opening for elimination of 
body wastes) is very rarely needed for colon cancer and is infrequently required for rectal 
cancer. Treatment of rectal cancer includes surgery besides chemotherapy alone or with 
combination with radiotherapy before, after, or both it. Chemotherapy is most used after 
colon cancer surgical removal for colon which spread to lymph nodes (ACS, 2011). Recent 
ongoing research in CRC introduces new approaches to control the side effects which 
related to treatment. 
The palliative care is the control of physical symptoms, attention to the social, 
psychological and spiritual needs of the patient and his family, beside the assessment, early 
identification, and treatment of pain and other problems of a physical, psychosocial or 
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spiritual nature to reduce suffering and improves the quality of life of cancer patients and 
their families (WHO, 2009). 
 
2.2.10 Burden of colorectal cancer 
2.2.10.1 Global burden of colorectal cancer 
 
CRC is the third most occurrence cancer in men (it accounts about 10% from all men 
cancers), and the second in women (it accounts 9.2 % from all women cancers) worldwide. 
Incidence of CRC differs widely across different regions of the world, almost about 55% 
of CRC cases occurs in more developed countries with lower mortality rates compared to 
high mortality rates and increasing incidence trends in less developed countries (IARC, 
2017).  
ACS (2015a) report show that CRC is the third most common cancer for both sexes, and it 
ranks the third in terms of mortality from all deaths attributable to cancer in the United 
State of America (USA). Previous study was done in Denmark showed that CRC is the 
third most common male cancer and second female cancer in Denmark, like many Western 
countries (Iversen et al., 2012). Also in United Kingdom (UK) CRC is the third major 
common cancer in female and males (Cancer Research-United Kingdom, 2013). 
 
2.2.10.2 Burden of colorectal in Eastern Mediterranean Region (EMRO). 
 
WHO (2009) expected that Eastern Mediterranean Region will has the highest increasing 
incidence rate of CRC among all WHO regions in the coming two decades, while the 
recent reports show low survival rates for diagnosed CRC in the region comparable with 
the developed countries. Previous study was carried out in Saudi Arabia, mentioned that 
CRC is the most common cancer among men and the third commonest among women 
since 2002 in Saudi Arabia, it added that the overall 5-year survival rate was 44.6% for the 
period 1994-2004 (Alsanea et al., 2015).  
Another previous study was carried out in Lebanon showed that colorectal cancer is the 
second major cancer in female and ranks the fourth among male cancers (Shamseddine et 
al., 2014). Recent studies were done in Iran have shown rapid rise in the incidence of CRC 
making the CRC to become the third most common cancer in Iran (Dolatkhah et al., 2015). 
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2.2.10.3 Burden of colorectal in Palestine 
 
In the most recent report about cancer in Gaza strip which is prepared by Palestinian 
Cancer Registry (PCR) and disturbed by MOH in GS, mentioned that the top five cancers 
in the Gaza strip are breast Cancer, CRC, lung Cancer, leukemia, and lymphoma 
respectively as shown in annex (4). The same source added that the CRC is the most 
common type of cancer among men and the second among women after breast cancer, 
where CRC accounts 10% of all cancer occurred in the period 2009-2014 with incidence 
rate about 45/100000 (MOH, 2015a). 
In the WB, cancer statistics do not significantly differ from statistics in GS, where the 
breast cancer is the most common cancer with 17.8 % from all registered cancer cases, 
followed by CRC with 9.4 % in 2015 among both sexes combined, while the lung cancer is 
the most common cancer among male followed by CRC (MOH, 2016a). Previous Study 
was done in north West Bank mentioned that the most common cancer for men is CRC 
which ranks the second for women cancer (Tanjeer, 2010). Cancer is the second most 
common cause of death in Palestine after cardiovascular diseases with rate 13.8% of all 
deaths in 2015 (MOH, 2016b). In Gaza strip 10.7% from all deaths occurred in 2015 
attributable to cancer which considered the second most common cause of death (PHIC-
MOH, 2016). Moreover, due to many cancer services are not available in Palestine 
particular in GS such as (radiotherapy, many chemotherapy drugs, PET CT, and others), 
MOH routinely refereed many cancer cases to have treatment abroad (such as East 
Jerusalem, WB, and others). So cancer diseases are on the top of causes for treatment 
abroad. In 2015, treatment abroad as overall costed about 147.5 million USD (560,873,668 
NIS). Cancer treatment only rather than the diagnostic procedures hauled about third of 
that number with 40 million USD (150,836,724 NIS) divided as about 10 million USD 
(36,787,515 NIS) for the cases from GS, and about 30 million USD (114,049,209) for the 
cases from WB (MOH, 2016).  
 
2.2.11 Colorectal cancer survival 
 
Recent years bear witness to remarkable progress and development on CRC management 
such as advancement on treatment protocols, improvement in surgical intervention, and 
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useful screening tools which resulting in improvement of CRC survival rate and more 
better progression of CRC (Hassan et al., 2016). The 5-years survival rate is the most used 
indicator for cancer survival which is measured as the proportion of cancer patients who 
still alive five years after diagnosis of cancer, comparable to five year survival of people in 
general population at same age and sex. Many factors affect on CRC survival, the most 
important factors are stage at diagnosis and the early detection of the tumors (ACS, 2011). 
According ACS (2016a), the 5-years survival rate for patient who are diagnosed at a local 
stage (stages I, and  II) is 90.3%, while for patients who are diagnosed with regional stage 
(stage III) is about 70.4% and the survival rate declines sharply for patients who are 
diagnosed with distant-stage (stage IV) with the lowest rate 12.5%.  
In USA, about 1.2 million Americans survived from CRC due to the progress in the early 
detection and the advancement in treatment, besides that there is significant improvement 
in the overall 5-years survival rate for colon cancer which was 50.6% in 1970 and became 
65.4% in 2012, and for the same period the 5-years survival rate for rectal cancer improved 
from 48.1% to 67.7% (Siegel et al., 2014). 
 
2.2.12 Variances in colorectal cancer survival over the world 
 
There are wide international differences in cancer survival rates especially between the 
developed countries and the less developed countries. Behind these differences are many 
factors such as differences in screening, treatment, detection practice, awareness, and data 
quality. CRC from cancers which is significantly affected by early detection and treatment 
which are considered the main causes for CRC survival differences between economically 
developed and developing countries (ACS, 2011). 
London School of Hygiene & Tropical Medicine with collaboration from the Union for 
International Cancer Control launched at 2008 CONCORD program, which is the global 
program for world-wide surveillance of cancer survival. To date CONCORD program is 
considered the most comprehensive international comparison of cancer survival, which 
covers countries in five continents. Two CONCORD studies was conducted which called 
CONCORD-1 and CONCORD-2 while final work is doing to publish CONCORD-3 study 
(Cancer Survival Group, 2017).  
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In CONCORD-1, the focus was on three main cancers (breast cancer, colon cancer, and 
prostate cancer) for patients who diagnosed in the period 1990–94 and followed up to 
1999. CONCORD-1 study showed wide global differences in 5-years survival rate for 
CRC patients, which were generally high in North America, Australia, Japan, and northern, 
western, and southern Europe, comparable with low rates in Algeria, Brazil, and eastern 
Europe (Coleman, 2008). CONCORD-2 studied the 5-years survival for patients diagnosed 
between 1995 and 2009, using data from 279 cancer registries in 67 countries, and it 
included ten common types of cancers include CRC. CONCORD-2 like CONCORD-
1showed very large variations between countries in survival rates for specific cancer, but it 
outlined that 5-year survival from CRC has increased steadily in most developed countries, 
where it reached in many countries 60% (Allemani et al., 2015).  
In USA, the overall 5-years survival rate exceeds 64%, while in Asia at approximately 
60% with best survival rate in China and the poorest in India. In Korea, reports indicated 
that the 5-year survival rates was 62.1%, while study conducted in china showed that 5-
years survival rate was  62.3%. Furthermore study conducted in Japan showed that 5-years 
survival rate for CRC was 61.4%. Previous studies in India showed the lowest 5-year 
survival rate in Asia with rate 31.2% (Moghimi-Dehkordi, and Safaee, 2012). Another 
Study conducted in Jordan to analyze survival rate for CRC showed that relative 5-years 
survival rate in Jordan was 57.7% (Al Nsour, 2014). Another study conducted in Iran 
showed that 5-years survival rate was 58.5% (Zare-Bandamiri et al., 2016). Also another 
study conducted in Malaysia revealed that 5-year survival rate was 59.1% (Suan et al., 
2016). 
Annex (5) shows the survival differences in 5-years survival rate from colon cancer. Data 
was obtained from CONCORD-2 study which provided survival analysis data for cancer 
diseases in 67 countries (Allemani et al., 2015). 
 
2.2.13 Factors affecting survival rate for colorectal cancer 
After systematic review of literature was been done, the researcher classified the main 
factors which may affect on the survival rates from CRC into three groups. The following 
paragraphs explain the impact of each factor from the three groups on CRC prognosis and 
the survival rates.    
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2.2.13.1 Patient Related Factors 
 Age at diagnosis 
 
Based on previous studies, the effect of age on prognosis and survival from CRC is 
argumentative subject. McKay and colleagues (2014) studied the influence of young age 
on the prognosis of CRC in Canada, and they found that young age is an independent 
factor for good prognosis and better survival, while the old age associates with poor 
prognosis because they usually presented with advanced disease and co-morbidity. While 
van Eeghen and colleagues (2015) have showed different effect of age at diagnosis for 
colon cancer patients and rectal cancer patients where the age at diagnosis significantly 
affects on the survival of colon cancer, but there is not significant effect on survival of 
rectal cancer. 
Another study was conducted on USA showed no differences in survival rate among 
patients aged below 50, or above 50 up to 80 years old, while patients aged above 80 years 
old experienced with poor survival rate (Steele et al., 2014). 
 
 Gender 
 
Many recent studies showed slightly survival differences between female and male CRC 
patients. Study was done in Germany by analysis of 164966 CRC cases between 1997 to 
2006, outlined that age-adjusted five years relative survival rate was slightly greater in 
women than men, and survival benefits go to those younger than age 45 years old (Majek 
et al., 2013). Another previous study was done in USA demonstrated significantly longer 
adjusted survival rates for women rather than men (Paulson et al., 2009). Furthermore 
previous study conducted in South Korea showed poorer survival rates among women aged 
over 65 years old than men (Kim et al., 2015). 
 
 Marital status 
 
Many research studies through literature showed that marital status has strong association 
with prognosis of many cancer diseases. Regarding CRC, survival benefits go to married 
patients rather than unmarried patients (Li et al., 2015). Lai and colleagues (2010) studied 
the association between marital status and survival rates from colon cancer. They 
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demonstrated that there are fairly modest survival differences between the married and the 
unmarried patients with colon cancer. Even though the married patients have slightly better 
survival rates than the unmarried patients. The authors showed that married patients may 
have better access to health care system and they diagnosed early, but when cancer stage 
was controlled, the survival differences decreased between the married and the unmarried 
CRC patients (Lai et al., 2010). 
Another previous study was done in Denmark found that five years survival rate for 
married colon cancer patients is significantly better than unmarried colon patients, but 
there were no survival differences regarding the married and the unmarried rectal cancer 
patients (Johansen et al., 1996).  
 
 Residency 
 
A systematic review of the literature points wide survival differences from cancer diseases 
between countries and regions. These differences extend within the boundaries of a single 
country itself.  Previous study was conducted in South Australia showed that CRC patients 
who live in the remote areas had significantly poorer prognosis than those live in the urban 
areas (Beckmann et al., 2016). Another previous study was done in Iran outlined that 
district residency have a significant impact on 5-year survival rate for colon cancer 
patients, and it added that , there are survival differences between western and southern 
regions of Iran (Heidarnia et al., 2013). 
 
 Co-morbidity 
      
Co-morbidity is defined as the “coexistence of disorders in addition to a primary disease of 
interest.” (Sarfati et al., 2016). Many previous studies have shown poorer survival rates 
among cancer patients with co-morbidity. Sogaard and colleagues (2013) have studied the 
impact of co-morbidity on cancer survival by reviewing more than 2,500 articles related to 
co-morbidity effect on cancer, and they found that the patients with co-morbidity have 
poorer survival rates than those without co-morbidity. 
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Previous study was conducted in Netherland showed that co-morbidity significantly 
impacted on overall survival from CRC. It's added that co-morbidity affected significantly 
survival for colon cancer patient, but did not significantly affected for those with rectum 
cancer (van Eeghen et al., 2015).  
 
 Work 
 
Work environment is considered one from the risk factors for CRC (Arbman et al., 1993). 
CRC affects on the ability of the patients to engage the usual occupational activities during 
cancer treatment and survivorship periods (Shipp et al., 2015). In this study, the work is 
defined as a variable may affects on the survival rates from CRC, but the scarcity of data in 
patients' medical records regarding the patients work impeded the study of work impact on 
CRC prognosis. 
 Education 
 
Many previous studies have showed association between the patients' educational level and 
survival rates from CRC. The previous studies showed that the survival benefits goes to 
more educated patients, and there is strong and inverse relationship between education 
level and mortality from CRC. Moreover the overall survival rates from CRC for high 
educated patients is better than those with low education level (Albano et al., 2007;  
Antunes et al., 2016; Cavalli-Björkman et al., 2011). In this study, the majority of patients 
medical records which is considered the main data source for the study, do not contain any 
data about the educational level for the patients, so study the impact of educational level on 
survival rate from CRC is unachievable.   
 
 Health-related behaviors 
 
There is growing evidence that lifestyle factors which include obesity, physical activity, 
and diet are associated with CRC prognosis, moreover studies showed that having normal 
weight, engaging in regular physical activity, and eating healthy diet are potential critical 
elements and preventive measures to improve survival rate among CRC patients (Lee et 
al., 2015a). 
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Even though smoking is considered as risk factor for many cancers including CRC, but the 
evidence regarding its impact on the prognosis of CRC patients remains sparse. Previous 
population-based study consists from 3130 CRC patients, showed that smoking associated 
with decreased survival rates among patients with non-metastatic colon cancer. The 
authors suggested that the association may be more pronounced in men rather than women 
(Walter et al., 2015).  
Previous study was conducted in USA concluded that long-term smoking increased the risk 
for death from CRC in both gender. Also the adjusted mortality rates for lifelong non-
smokers patients are lower than former or current smokers' patients (Chao et al., 2000). 
Another study was conducted in USA outlined that the total tobacco usage early in life 
may be an important independent prognostic factor for cancer recurrences and death in 
patients with stage III colon cancer (McCleary et al., 2010). 
There is few studies focus on relationship between survival from CRC and diet before or 
after diagnosis of CRC (Lee et al., 2015a). Previous study was conducted in France to 
analyze the influence of dietary factors on survival from CRC, showed that five years 
survival rate was affected by pre-diagnosis diet. Furthermore the authors have showed that 
high carbohydrate, protein, and lipid intake, is strongly related to increase survival benefits 
for CRC cases (Dray et al., 2003). 
According WHO (2006), the BMI is a simple index of weight-for-height which it is 
commonly used to classify underweight, overweight and obesity in adults. It is defined as 
the weight in kilograms divided by the square of the height in meters (kg/m2).  
Obesity increase risk for CRC, but there is no conclusive evidence showed that obesity has 
direct negative effect on survival rate from CRC (Bardou et al., 2013).  
Regarding physical activity, many previous studies indicated that physical activity 
associated with positive effect on colorectal cancer survivors and reduce risk of disease 
recurrence       (Cassileth et al., 2016). Beside that non-metastatic patient who are more 
physical active have low mortality rate than those with low physical activity (Meyerhardt 
et al., 2009).  
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2.2.13.2 Tumor Related Factors 
 
 Histological type 
 
According to WHO classification, there are a number of histological types of colorectal 
carcinomas such as an usual adenocarcinomas, mucinous, signet ring cell, and others 
(Fleming et al., 2012). Usual adenocarcinomas are the most common colorectal carcinomas 
constitute about 85%, while the mucinous adenocarcinomas are the second most common 
type constitute about 10 to 15% from all colorectal carcinomas, whereas the other types are 
very rare (Lanza et al., 2011). 
In this study, the usual and the mucinous adenocarcinomas are studied, so the patients are 
classified to two groups, the patients with non-Mucinous Adenocarcinomas (non-MAC) 
and the patients with Mucinous Adenocarcinomas (MAC).  
Previous large-scale study was conducted in South Korea enrolled a total of 6475 CRC 
patients with stage I–III, showed that 95.8% from patients were with non-MAC, and 4.2 % 
were with MAC. And it demonstrated that major patients with MAC have tumor in right 
colon and they were younger, tumor sizes larger, and more advanced status than patients 
with non-MAC. Moreover the study showed that mucinous histology has not an 
independent effect on prognosis. However, patients with non-MAC have better survival 
rate than patients with MAC (Park et al., 2015). 
 
 Tumor Grade 
 
To date, the most widely used system of defining CRC’s histological grade is based on the 
percentage of tumor glands which are forming the mass. Tumor grade is an important for 
defining treatment and indication for tumor prognosis. 
As general, a lower grade related with better prognosis, while high grade correlated with 
poor prognosis and need more aggressive treatment (ACS, 2015c). Also Canadian cancer 
society emphasizes that high grade CRC indicates poor prognosis rather than lower grade 
(Canadian Cancer Society, 2016). 
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Previous study showed that tumor grade is associated with survival from CRC, in tumors 
with stages II, III, IV rather than stage I at date of confirmed diagnosis (O’Connell et al., 
2004). 
  
 Stage at diagnosis 
  
Stage at diagnosis is considered the main and the strongest factor determines the cancer 
prognosis. CRC with lower stages associates with better prognosis and higher survival 
rates rather than CRC with advanced stages (Canadian Cancer Society, 2017). Previous 
large scale study was conducted in USA included 119363 patients were diagnosed with 
CRC in the period from 1991to 2000, shows significant differences in 5-years survival rate 
among patients based on stage of CRC at diagnosis, and it outlined that 5-years survival 
rate for patients who were diagnosed with stage I was 93.2%, 82.5% for patients with stage 
II, 59.5% for stage III, and 8.1% for stage IV (O’Connell et al., 2004). 
Another previous study was conducted in three European countries (Switzerland, France, 
Spain) to study impact of stage at diagnosis on survival from rectal cancer outlined that the 
main factor for survival differences between the three countries was stage at diagnosis 
(Monnet et al., 1999). 
 
2.2.13.3 Healthcare Related Factors 
2.2.13.3.1 Diagnostic related factors 
 Diagnostic delay 
 
To date, the effect of diagnostic delay on cancer prognosis is still argumentative subject, 
and there is no clear evidence on this subject. Despite of cancer is progressive disease, so is 
expected to be affected by delay whether in diagnosis or treatment (Foot and Harrison, 
2011). There are different definitions and sub-classifications of diagnostic delay through 
literature. In this current study, the researcher studied diagnostic delay as the period from 
onset of symptoms until date of confirmed diagnosis by histo-pathological evidence. Pita-
Fernández and colleagues (2016) defined symptom to diagnosis interval (SDI) as the time 
from the diagnosis of cancer and the first symptoms related to CRC. The authors outlined 
that short SDI were significantly associated with lower survival rate in rectal cancer, 
modest effect were observed in colon cancer cases. 
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 Signs and symptoms of CRC 
  
Blooding per rectum, abdominal pain, change in bowel habits constipation/diarrhea, and 
unexplained anemia are main signs and symptoms associated with CRC cancer. 
Symptomatic patients at diagnosis usually have advanced disease so dramatically have 
poor prognosis. There are inverse relationship between number of signs and symptoms and 
survival from CRC (Macrae et al., 2016). 
 
2.2.13.3.2 Treatment related factors  
 Treatment delay 
 
Association between survival and waiting time from diagnosis to initiation of treatment is 
still argumentative issue. Shandiz (2016) defined the interval to treatment as "the time 
between date of pathological diagnosis, usually via open biopsy, and the date of initial 
therapy, either surgical or systemic". Previous study was conducted in USA showed that 
longer interval to treatment up to one year has no strong effect on CRC-specific deaths. 
The authors suggested that the screening remains the primary goal to reduce CRC 
mortality (Pruitt et al., 2013).  
Another previous study shows that there are not significant relationship between treatment 
delay and CRC survival rates (Murchie et al., 2014).  
 
 Treatment places (Gaza Strip, West Bank, East Jerusalem, Egypt, Israel, 
others) 
MOH purchases many services for cancer management from many places inside Palestine 
and outside Palestine to treat GS patients who their treatment plan need more advance 
diagnostic procedures or treatment protocol are not available in MOH hospitals inside GS. 
The main places for treatment abroad for GS CRC patients are (West Bank, East 
Jerusalem, Egypt, Israel, and Jordan) (MOH, 2016). In this study the researcher study how 
different treatment places affect on survival from CRC. Treatment place is divided to two 
domains: Inside GS, and outside GS. 
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 Treatment types  
1. Surgery 
  
Many studies around the world show that the surgery is considered the most effective 
treatment approach for CRC patients. For patients with stage I and II can cure completely 
by surgical resection of tumor alone, while for those with stage III need beside surgical 
intervention chemotherapy.  
In the opposite, for those with stage IV with unresectable metastases there is uncertainty 
about the effectiveness of the surgical resection. However, the palliative surgery may be 
needed in some conditions such as complete bowel obstruction and uncontrolled bleeding 
(Biondi et al., 2016). 
As the surgical resection remain the only curative method for CRC in the early stages and 
even with liver metastasis, the multidisciplinary treatment management stills the way to 
conduct the proper treatment plan and gain the best results (Patrlj et al., 2014). 
 
2. Chemotherapy 
 
Chemotherapy is treatment approach which chemicals such as (5Fluorouracil (5-FU), 
Camptosar, Xeloda, Eloxatin, and Lonsurf ) is used to kill rapid divided cells such as 
cancer cells. In CRC, used of chemotherapy and its components based mainly on CRC 
stage. There is no need of chemotherapy in CRC at stage I, while for rectal cancer stage II 
and high risk patients with colon cancer at stage II, chemotherapy is used. In stage III and 
IV chemotherapy often is used if there no thing stops it such as patient health status and 
availability of drugs. The most common used chemotherapy regimens are FOLFOX 
(leucovorin, 5-FU, and oxaliplatin), FOLFIRI (leucovorin, 5-FU, and irinotecan), CapeOX 
(capecitabine (Xeloda) and oxaliplatin) and FOLFOXIRI (leucovorin, 5-FU, oxaliplatin, 
and irinotecan) and there are other combinations and generations (ACS, 2016b). As general 
use of chemotherapy combination in treating advance CRC is relating with better outcomes 
(Cancer-Connect, 2017). Furthermore many previous studies have showed that patients 
with advance CRC who received chemotherapy  have more better survival rate than those 
who did not received chemotherapy, also they suggested that chemotherapy reduce disease 
recurrences rate, disease relapse, and improved quality of life )Leydon, et al., 2000; Texas 
Oncology, 2017; Ragnhammar et al.,2001; Milinis et al.,  2015).   
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3. Radiotherapy 
 
Radiotherapy  is defined as the use of high-energy rays (such as x-rays) or particles to 
destroy cancer cells, and to make radiotherapy more effective against some colon and 
rectal cancers, it is used with combination with chemotherapy, in this case they called 
chemoradiation (ACS, 2016b). Radiation therapy has assumed an integral role in the 
treatment of colon and rectal malignancy when combined with potentially curative 
resection and may be used in either an adjuvant or neo-adjuvant manner (Dixon and 
Stamos, 2005). According ACS (2016b) radiotherapy is must used for colorectal cancer in 
many situation either before or after surgery such as treating distant metastasis to bone or 
brain, partial surgical removal of tumor when it attached to an internal organ, and also is 
used to palliate ease symptoms such as intestinal blockage, bleeding, or pain in patients 
with unresectable tumors.   
 
4. Palliative care 
 
In recent years, the palliative care has attracted more attention where the palliative care by 
controlling of symptoms and decreasing suffering become the goal of treatment, when cure 
of cancer is not possible. There are many different strategies of non-surgical palliative care 
methods offered to advanced CRC patients such as (Chemotherapy, radiotherapy, pain 
management, endorectal metallic stent placement, and laser recanalization) beside the 
surgical palliation (Dixon and Stamos, 2005). In this current study, the first three methods 
(Chemotherapy, radiation therapy, and pain management) are studied.  
As general, the patients with advanced CRC (Stage IV) who received palliative 
chemotherapy have prolonged time to disease progression and better survival than those 
who did not received chemotherapy (Colorectal Cancer Collaborative Group, 2000). Also 
palliative radiotherapy play an effective role in controlling symptoms such as pain and 
bleeding. While for non-chemotherapy/non-radiotherapy methods for controlling pain, the 
oral opioids is considered the first line for patients with an effective effect, this is beside 
other drugs such as amitriptyline, gabapentin, and other approaches (Dixon and Stamos, 
2005). 
Another recent study shows a dramatic improvement in the expected survival from 4-6 
months to more than two years, for CRC patients with advanced stages who received best 
supportive palliative care (Costi et al, 2014). 
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Chapter (3) Methodology 
3.1 Study design 
 
Observational analytical retrospective cohort study (non-concurrent prospective) design 
was used in this study. The researcher analyzed the survival rate of CRC cases who were 
diagnosed in the period (2008-2010) in GS and follow up them for 5 years to determine the 
overall 5-years survival rates.  
Retrospective cohort studies are suitable for this study, because it allowed the researcher to 
examine many factors that may affect on the survival rates from CRC in short period 
relatively and this design of studies is less expensive, that enabling the researcher to 
achieve the study general and specific objectives in short period and with low cost. 
Furthermore it is characterized with low bias, because the used data is already collected for 
other purpose of this study. 
 
3.2 Study population 
 
The study population is all CRC patients who were diagnosed in the period (2008-2010) in 
GS. List of 255 CRC cases were diagnosed in the period 2008-2010 was retrieved from 
PCR in GS. According the study inclusion and exclusion criteria, only 184 cases are 
eligible for this study, where 71 cases are excluded for different causes. The 184 cases are 
added to them 23 cases from patients' database in Al-Shifa hospital and EGH, hence the 
total number for the study cases become 207 cases. For more detailed information see 
annex (7) which describes with details the selection process of the study cases. 
 
3.3 Study setting 
 
The study was population based and conducted in main four areas  
1. Al-Shifa hospital (Information technology unit, Central archive, and 
Histopathological lab). 
2. Rantesi Specialist Pediatric Hospital-RSPH (Due to the transfer of adult oncology 
and hematology services which were in Al-Shifa hospital to RSPH, because of 
rebuilding in many departments in Al-Shifa hospital). 
3. European Gaza Hospital (Oncology and hematology services including archive, 
and information technology unit). 
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4. Ministry of Health (Cancer registry center, Central archive, Deaths and births 
registry directorate) 
 
3.4 Study period 
 
The School of Public Health-SPH at Al-Quds University accepted the study proposal at 
end of May, 2016. After that proposal copy was sent to Helsinki committee in GS to assign 
ethical approval for the study. Helsinki Committee approved the study proposal at August, 
2016 (annex4). Then Administrative and approval letters with copies of Helsinki approval 
were sent to MOH (Human Resources Development Directorate) in August, 2016 
(Annexes 5, 6). Data collection journey started from cancer registry at beginning of 
September, 2016 extended to January, 2017. 
Data entry on SPSSversion-22 was done alongside data collection. Re-entry of 5% data (11 
medical records), re-checking of the missing data and data filtering were finished at 
beginning of February, 2016. Data analysis and discussion of main findings were 
consuming about three weeks. The research report was ready at end of March, 2016. As 
general the study consumed about 14 months, began at March 2016 and finished at May, 
2017.     
 
3.5 Eligibility criteria 
3.5.1 Inclusion 
 
The study includes all CRC cases who were diagnosed in the period between (2008- 2010), 
and recorded in Al-Shifa hospital, EGH, or PCR and their medical records are available, 
except any case met any of exclusion criteria.  
 
3.5.2 Exclusion 
1. CRC cases who were diagnosed before 1/1/2008 (2 cases).  
2. CRC cases who were diagnosed after 31/12/2010 (8 cases). 
3. CRC cases from outside GS and they were been diagnosed inside GS (1 case). 
4. Cases who were diagnosed with other cancer rather than CRC (5 cases). 
5. CRC cases who were diagnosed in 2008-2010 with unavailable medical records (55 
cases). 
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3.6 Study instruments 
 
The data abstract sheet (Annex 10) is constructed to make the data collection process from 
the medical records and other data sources more smoothly and more organized. Also the 
data entry in the analytical programs becomes more easy and smooth. 
 
3.6.1 Main Items for Abstract sheet 
 
 Socio-demographic information (Age at diagnosis, gender, marital status, work, 
area 
           of residency, and education). 
 Patient Health profile (Patient history, family history, chronic diseases, health risk 
            factors behaviors such as smoking, high fatty diet , physical inactivity ....) 
 Tumor characteristics (Histological type, stage at diagnosis "TNM", tumor 
grade). 
 Health care management information 
- Diagnosis process: (Date of initial symptoms and signs related to CRC began to 
appear, first visit to health care facilities related to symptoms and signs, date of first 
diagnostic procedure, date of taking the biopsy from the tumor, and date of 
confirmed diagnosis). 
- Treatment information: date of initial treatment (which is surgery, 
chemotherapy), date of first time of radiotherapy, palliative therapy, and the 
treatment places.  
 Progression information 
               - Metastasis information (Metastatic case/non-metastatic case). 
               - Vital Status information (Alive/dead). 
 
3.7 Scientific rigor 
3.7.1Validity 
 
The abstract sheet was constructed by the researcher with help from the supervisor. The 
abstract sheet items are enough to cover all needed information for study variables in order 
to achieve the general and specific objectives of the study.  
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Data abstract sheet was introduced to health care professional in the oncology department 
at Al-Shifa hospital and the experts to give their feedback about the abstract sheet contents, 
arrangement of items in the abstract sheet. Advices and notifies (which relevant to study 
specific and general objectives) were taken into consideration when the researcher went to 
prepare final copy of abstract sheet. Also the researcher carried out pilot study before 
actual data collection to ensure the validity of data abstract sheet content.  
 
3.7.2 Reliability 
 
 Data abstract sheet was standardized and each abstract sheet was coded with serial 
number. 
 Frequent and daily checkup of abstract sheet was done immediately after it is 
completed at field to find missed data and completeness of abstract sheet. 
 Data entry was been in parallel with data collection 
 Data collection was done by the researcher himself, and to ensure the accuracy of 
data entry 5 % of data had been re-entered (11 medical records). 
 The medical records are the main source data for data to complete the abstract 
sheet. In case of unreported items in the medical records, the researcher tried to find 
the missed information from patients' information database in Al-Shifa hospital, 
EGH, death certificates, histopathological records. 
 To avoid duplication of cases each case is defined by full name, her national 
identity number and coded with serial number. 
 
3.8 Ethical and administration consideration 
The researcher asked for all ethical and administrational considerations which are required 
to conduct the study, and he was committed to these considerations from the study start till 
the end. Firstly an academic approval was taken from the Al-Quds University-SPH, was 
followed by taken an ethical approval from Helsinki Committee to carry out the study 
(annex 4). SPH sent an administrational letters to MOH (Human Resources Development 
Directorate and Primary Health Care Directorate), where MOH approved to allow 
conducting of the study (annexes 5 and 6). The researcher is committed to academic 
honesty and high confidently precautions over study period (data collection, data entry, 
analyses and respect to research results).  
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The researcher set a plan to share the study results locally and international to get 
maximum benefits from the study. Hard copies form the final study report will be 
distributed to local university and college, whereas electronic copies will be distributed via 
international medical journals.  
3.9 Pilot study 
 
The pilot study was conducted before actual time of data collection had began, where 
fifteen medical records were included in the pilot study, which are distributed as the follow 
(Five medical records for cases who were diagnosed in 2008 year, five cases from 2009 
year, and five cases from 2010 year). The pilot study was conducted by the researcher to 
assure validity of data abstract sheet, and to assess the quality and quantity of data 
available in the medical records which are considered the source for data in this current 
study.  
The pilot study give chance for examining the reporting status of study variables in the 
medical records and arrangement of data in them. The pilot study shows different quality 
and quantity of reporting items between the medical records, but the available data in the 
medical records is enough to conduct the study.  
After the pilot study was finished, minor modifications had been done on data abstract 
sheet. The fifteen cases which are included in the pilot study, also they are included within 
the study. 
 
3.10 Data collection 
 
After the final modification on data abstract sheet have been done and the pilot study have 
been carried out, the researcher himself began to collect data from the main sources which 
was the medical records for the study cases. 
 The medical records for CRC cases are present in four places: The oncology outpatient 
clinic archive in SPH, EGH archive, the main archive in Al-Shifa hospital, and MOH-
central archive as described in table (3.1).  
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Table (3.1) Distribution of medical records for all study cases according their 
Location 
 
Location of medical records 
Living status 
At time of Data 
collection 
No. of            
the medical 
records 
(%) percent 
Oncology outpatient clinic 
archive in SPH 
Alive 52 24.6% 
EGH archive Alive 36 17.4% 
The Main archive in Al Shifa 
hospital 
Dead 27 13% 
MOH-Central archive Dead 92 45% 
Total Alive/Dead 207 100% 
 
3.11 Data entry and analysis 
 
Statistical Package of Social Science (SPSS) program version-22 was used for data entry 
and analysis. Data entry took place parallel with actual data collection began. All abstract 
sheet copies were organized and coded with serial number code. Data entry was done by 
the researcher himself. After data entry had been finished, the researcher re-entered 5% 
from data abstract sheet copies (11 abstract sheet). Also all entered data on SPSS was 
reviewed for missing or wrong data (Data cleaning). Data analysis includes the forming of 
frequency tables, selected graphs, to show main characteristic of study population and 
main study findings related. Survival analysis was done by using Kaplan-Meier method to 
estimate overall survival times and rates. A univariate analysis was conducted to show 
impact of main study variables on the survival data such as stage at diagnosis, treatment 
type, and place of treatment. Also the log rank test was used to estimate difference between 
the groups. The researcher considered the variable to have a significant effect if the P-
value ≤ 0.05, with 95% confidence interval.  
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Cox-regression analysis is conducted to verify how far these differences between groups 
are statistically significant (P-value ≤ 0.05).  
After overall survival rate for the entire population was estimated, the cases are divided 
into two sub-groups, where the first group is non-metastatic cases and the researcher 
determines the overall survival rate and disease free survival rate for them. The second 
group is metastatic cases; overall survival rate and progression free survival rate for them 
were determined. 
  
3.12 Limitation of the study 
 
 Hard access to the medical records, especially for the dead cases.   
 Poor quality of documentation and organization of data in the medical records and 
the missed data in the majority of the medical records with different degrees.  
 Weak coordination between hospitals and the central archive and the high number 
of the missed medical records, 
 Absence of computerized archiving system except the central archive.   
 Small body of previous research studies in Arabic region including Palestine 
regarding the survival analysis of CRC and the main aspects and factors which have 
effect on CRC progression and the survival rate. 
 Cases that were eligible for the study were 207 cases, it is small number compared 
to the international studies.  
 Radiotherapy, chemo-radiation, and PET CT, are not available at GS neither 
governmental nor private sectors, so many medical records miss information about these 
services.    
 TNM staging of CRC are missed in the majority of the medical records. So the 
researcher with kind help from the supervisors and the oncologist in EGH conducted the 
TNM staging system for all missing records which consumed additional time, and 
efforts. 
 Study population is limited only to the medical records of the cases, so there is no 
any contact between the researcher and the study cases or their families to complete any 
missing data from the medical records. 
 This study was first study conducted in GS regarding CRC progression, so the 
comparison with previous results is not possible. 
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Chapter (4) Results and Discussion 
4.1 Descriptive analysis 
4.1.1 Socio-demographic characteristics of study population 
 
Study population is all CRC cases who were diagnosed in the GS at the period (2008-
2010), which are 255 cases according list retrieved from PCR. After exclusion of some 
cases due to for various causes, only 207 patients were eligible for this study Annex (7).  
Crude incidence rate for the included CRC cases in GG who were diagnosed at period 
2008-2010 was 14 per 100000 (207/1,486,816*100000), which was calculated by dividing 
the total number of the study cases on GS population at the mid-study period (mid-2009 
year) as shown in table (4.2). This finding is lower than the rates according PCR and these 
differences refereed directly to exclusion of many CRC from this current which decrease 
the total number of cases.  While the age adjusted rate for CRC in GS according PCR is 
16.2/100000 (MOH, 2015a). 
The following paragraphs will explain the main results and findings regarding the study 
cases socio-demographic characteristics and how study findings agreed or disagreed with 
other previous studies.  
 
4.1.1.1 Age at diagnosis 
The mean of age for the study population is 59.6, while the most frequent age group is 60-
69 years as shown in Table (4.1). Study findings show dramatically increase of CRC 
incidence with age where more than two third of the study cases occurred after age 50 
years old with 77.7%, while 22.3% below age 50 years old (figure 4.1). The literature 
shows wide global differences about mean of age at diagnosis for CRC cases, but there are 
compatible results, that the incidence of CRC increases with age especially after age 50 
years old. Previous study was conducted in USA have showed high age mean for CRC 
cases with 65.1 years (Lai and Stotler, 2010). Another previous study was conducted in 
Iran have showed low mean age with 53.5 comparable with current study findings (Fatemi 
et al., 2015). Another previous study was conducted in Egypt have showed lower age mean 
for CRC patients in Egypt with age mean 46 at time of diagnosis (Abu-Zeid et al., 2002).  
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Figure (4.1): Distribution of colorectal cancer cases according age at diagnosis group 
in GS (2008-2010) 
 
 
4.1.1.2 Gender 
 
Study findings show that male cases constituted 54.6% (113 cases) from the study 
population, while female cases constituted 45.6% (94) as shown in table (4.1). These 
findings were similar with findings from large scale study which included 164966 
colorectal patients in German, where showed that male patients accounted 52.6% and 
female patients 48.4% (Majek et al., 2013). And else study conducted in USA showed that 
53% from colorectal cases were male cases (Lai and Stotler, 2010). Another previous study 
conducted in Jordan showed similar findings with 54.2% of its population were male, 
while 45.8% were female (Al Nsour, 2014). In Iran, CRC study was conducted showed 
that 51.2% from total study population were male patients (Fatemi et al., 2015). 
Furthermore previous study conducted in Egypt showed slightly high percentage of male 
patient with 58.8% (Abou-Zeid et al., 2002). 
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Table (4.1): Socio-demographic characteristics of study population  
 
 
 
 
 Socio-demographic factors No. of cases Percent 
1. Age at diagnosis group 
 <40 13 6.3  % 
40-49 33 15.6 % 
50-59 52 25.1 % 
60-69 63 30.4 % 
>=70 46 22.2 % 
Total 207 100  % 
2. Gender 
 Female  94 45.4 % 
Male 113 54.6 % 
Total 207 100  % 
3. Marital Status 
 Married 172 83.1 % 
unmarried 34 16.4 % 
unreported 1 0.5  % 
Total 207 100% 
4. Residency  
 North Gaza 34 16.4 % 
Gaza 77 37.2 % 
Gaza Center 29 14.0 % 
Khan Younis 40 19.3 % 
Rafah 27 13.0 % 
Total 207 100  % 
5. Work 
 Unemployed 16 7.7  % 
Employed 14 6.8  % 
Unreported 177 85.5%  
Total 207 100 % 
6. Education 
 BS.C 8 3.9 % 
Unreported 199 96.1% 
Total 207 100% 
The mean of age at diagnosis for the study population is 59.6 years. 
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4.1.1.3 Marital Status 
 
As shown in table (4.1), most of study cases have available information about their marital 
status in the medical records except one case. The study findings show that 83.1% from 
cases were married at time of diagnosis and 16.4 were unmarried. This percentage of 
married cases is high if it is compared to many countries in the world. These differences 
may be refereed to nature of social relationships and culture of Arabic societies.  
Lai and Stotler (2010) in their study which was conducted in USA show that 65 % from 
CRC cases who were diagnosed in 1992-2003 were married at time of diagnosis. Another 
previous study was conducted in USA have showed that 58.4% from CRC cases were 
married at time of diagnosis (El-Haddad, 2015). Also low percentage of married CRC 
cases was showed in previous study was conducted in China with about 55.20% ( Li et al., 
2015).  
 
4.1.1.4 Residency 
 
According study findings, Gaza governorate records the high number of CRC cases who 
were diagnosed at the period (2008-2010), and as illustrated in table (4.1) 37.2% of the 
cases (34 cases) were from Gaza governorate. The least governorate records cases was 
Rafah with 27 case (13%), while North Gaza, Mid Zone, Khan Younis governorates 
constituted 16.4%, 14%, and 19.3% respectively. As shown in table (4.2) Gaza governorate 
had the highest incidence rate with 15.2 per 100000, followed by Khan Younis governorate 
with rate 14.4 per 100000 while North Gaza governorate had the least incidence rate with 
12 per 100000. Incidence rate for colorectal cases per 100000 for Gaza Center and Rafah 
governorates were 13.4, 13.1 respectively. In term of incidence rate North Gaza had the 
least incidence among the five GG, but according cases numbers Rafah governorate in the 
south of GS recorded the least number of cases at study period (2008-2010).  
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Table (4.2): Incidence rate for study population according Gaza Governorates  
Governorate No. of 
cases 
Population at mid study 
period (mid-2009) 
Incidence rate /100000 
North Gaza 34 286,246 12 
Gaza 79 519,027 15.2 
Mid Zone 29 215,808 13.4 
Khan Younis 41 283,286 14.4 
Rafah 24 182,449 13.1 
total 207 1,486,816 14 
 
4.1.1.5 Work 
 
Information about kind of cases work at time of diagnosis was missed in the majority of 
the medical records for study population. As shown in table (4.1) 30 medical records out 
from 207 medical records have information about patients cases work. From 30 cases, 16 
are unemployed and 14 are employed at time of diagnosis and there is no any additional 
information in the medical records. Due to few cases and scarcity of data about the study 
cases work, the analysis of work effect on the survival rate from CRC cases is not 
achieved.  
 
4.1.1.6 Education 
 
As shown in table (4.1) information about the educational level of CRC cases is absent in 
the majority of the medical recodes. There are no any medical records contained any  direct 
information about cases educational level except eight medical records have indirect 
information about education through type of cases occupation, but it is not enough to 
conduct the analysis about impact of educational level of cases on survival rate from CRC. 
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4.1.2 Patient medical profile  
 
Data about the general medical condition for the study cases are collected from the medical 
records. The main items are checked and analyzed (the presence of co-morbidity, family 
history of cancer, obesity status, smoking, physical activity status, and diet habits).  
Unfortunately no data are found about the diet habits or the physical activity status in the 
medical records so they are excluded from the analysis.  
Regarding the other variables, not all 207 medical records contain data about each variable, 
but the reported data as general is enough to conduct the survival analysis for theses 
prognostic variables. Table (4.3) summarized the main finding regarding the cases medical 
status. 
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Table (4.3): Distribution of the study cases according selected medical profile items. 
 
 
 
 
 Socio-demographic factors No. of cases Percent 
1. Age at diagnosis group 
 <40 13 6.3  % 
40-49 33 15.6 % 
50-59 52 25.1 % 
60-69 63 30.4 % 
>=70 46 22.2 % 
Total 207 100  % 
2. Gender 
 Female  94 45.4 % 
Male 113 54.6 % 
Total 207 100  % 
3. Marital Status 
 Married 172 83.1 % 
unmarried 34 16.4 % 
unreported 1 0.5  % 
Total 207 100% 
4. Residency  
 North Gaza 34 16.4 % 
Gaza 77 37.2 % 
Gaza Center 29 14.0 % 
Khan Younis 40 19.3 % 
Rafah 27 13.0 % 
Total 207 100  % 
5. Work 
 Unemployed 16 7.7  % 
Employed 14 6.8  % 
Unreported 177 85.5%  
Total 207 100 % 
6. Education 
 BS.C 8 3.9 % 
Unreported 199 96.1% 
Total 207 100% 
The mean of age at diagnosis for the study population is 59.6 years. 
46 
 
4.1.2.1 Co-morbidity 
Regarding the co-morbidity status, 155 medical records contained information about co-
morbidity status of cases. 66 patients (43%) out of 155 patients are found with co-
morbidity (HTN, DM, HTN+DM, or others) and 89 cases (57%) have not any other 
disease rather than CRC. From the 66 cases who have co-morbidity 37.9% had HTN, 
33.3% have DM, and 22.7% had DM and HTN together, and 6.1% had other diseases.  
In long with other studies, many findings show relatively high rates of co-morbidity among 
CRC cases. Previous study was conducted in Denmark outlined that about at least one third 
of cases had co-morbidities (Iversen et al., 2012). Another previous study was conducted in 
China also showed high percentage of co-morbidities among CRC case, where outlined 
that about 79% from CRC cases had at least one kind of co-morbidities diseases (Wang, et 
al., 2016). In the South of the Netherlands, previous study showed that 62% from CRC 
cases had co-morbidity (Van Leersum, et al., 2013).  
 
4.1.2.2 History of cancer 
 
Patient history data about cancer are found in 129 medical records, 10.8% (14 patients) 
have history of previous cancer and 89.2% (115 patients) have not history of cancer. While 
25.9% from study cases have positive family history of cancer, and 74.1% had negative 
family history of cancer. This study finding accord with other study conducted in Iran 
which showed that 24.5% from CRC patients had positive family history of cancer (Karimi 
et al., 2011). Zell and colleagues study have showed high percentage of positive family 
history of cancer among CRC cases with about 35 % (Zell et al., 2008). 
 
4.1.2.2 Obesity status  
 
To calculate Body Mass Index (BMI), 207 medical records are checked out for height and 
weight of patients at time of diagnosis. As overall the researcher found 154 medical 
records contain data about height and weight of patients. 
By using SPSS program, BMI is calculated for the cases who have data about their height 
and weight. Then the cases were classified to two groups (cases with normal weight-
BMI<24.9, and cases with overweight or obesity-BMI>25). The results are as the follow, 
66 patients (42.8%) were with normal weight, while 88 patients (57.2%) were over-
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weighted or obsess at time of CRC diagnosis (Table 4.3). Relatively these findings accord 
with Yuan and colleagues study which showed that about the BMI for about 61% of CRC 
cases were ≥25 kg/m2 at time of CRC diagnosis (Yuan et al., 2013).  
 
4.1.2.3 Smoking 
 
About smoking, as shown in table (4.3) 144 medical records have data about it. The study 
findings show that 88 patients (61.1%) are non-smoker, while 56 patients are smoker 
(38.9%). These results are more than results from previous study was conducted in Iran 
which showed that only 22.4% from CRC patients were smoker at time of diagnosis 
(Karimi et al., 2011). Also this study results is more than previous study was conducted in 
China which showed that only 14% from CRC cases were smoker (Yuan et al., 2013). In 
USA, previous study outlined that about 34% from CRC cases were former or current 
smoker at time of CRC, these results also lower than current study results with about 4%. 
These high rates of smoking among the study cases may be more attention to discover the 
causes behind that. 
 
4.1.3 Tumor characteristics 
4.1.3.1 Histological type 
 
Analysis of available data for 201 cases who have data about histological types of 
colorectal carcinomas show that the most common histological type is usual 
adenocarcinomas (Non-mucinous) with 86.7%. While mucinous adenocarcinomas 
accounted 11%, and 2.3% for other histological types (Table 4.4). Compared to other 
studies, O’Connell and colleagues (2004) have showed similar findings where the most 
frequent histological type among cases was adenocarcinomas 87.4%, while 11.6% from 
cases had mucinous adenocarcinoma (O’Connell et al., 2004). Also relatively similar 
findings in Al-Nsour study, which showed that 84.5% from colorectal carcinomas are 
adenocarcinomas and 7.8% are mucinous adenocarcinomas (Al-Nsour, 2014). In China, 
previous study illustrated that adenocarcinomas and mucinous adenocarcinomas accounted 
79.2 % and 16.8% respectively (Yuan et al., 2013). 
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4.1.3.2 Tumor grade 
As illustrated at table (4.4), 185 medical records had information about tumor grade, 14 
cases were found with tumor grade 1 (7.6%), 140 cases with tumor grade 2 (75.7%), 29 
cases with tumor grade 3 (15.7%), and only 2 cases with tumor grade 4 (1%).  
The study results are in line with a previous study was conducted in Jordan which has 
showed that 62.7% from CRC cases with moderate grade and 14.9 with poor grade (Al-
Nsour, 2014). Another previous study conducted in China showed relatively similar 
findings where well, moderate, and poor differentiation grade accounted 25.6%, 43.9%, 
and 20.1% respectively (Yuan et al., 2013).   
In USA, previous study demonstrated that 67.8% from CRC cases has low grade tumors, 
while 19.4% have high grade tumors (O’Connell et al., 2004) 
 
4.1.3.3 Stage at diagnosis 
 
The study findings regarding the tumor stage at diagnosis show that 190 patients out of 207 
patients have enough data about stage of CRC at diagnosis in the medical records. The 
study results outline that six patients (3.2%) were diagnosed with stage I, 67 patients 
(35.2%) with stage II, 40 patients (21.1%) with stage III, and 77 (40.5%) patients were 
diagnosed with stage IV. It is mean that more than the half of patients (61.6%) are 
diagnosed with advanced stages (III + IV) which directly poor prognosis of CRC in GS. In 
the other hand these results may give good space for future improvement by decreasing the 
rate of discovering cases with advanced stages. 
In line with other studies, previous study was conducted in Jordan revealed that low 
percentage of patients diagnosed with stage IV compared to the current study 24%, 40.5% 
respectively. Even though it showed that stage III and IV accounted 82.5% from all cases 
which is more than the current study finding which showed that these stages accounted 
61.6% from all cases (Al-Nsour, 2014). In the Netherlands, previous study showed that 
only 22% from CRC cases presented with stage IV lower than current study, while 25% 
presented with stage III, 33% stage 2, and 14% stage I (Lemmens et al., 2010).   
 
4.1.3.4 Tumor site  
Data about tumor site are found in 197 medical records. Analysis of findings showed that  
Left-sided colon are the most common site for developing CRC with 52.3% of all cases. It 
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followed with rectal cancer with 25.9%, while right-sided colon accounted only 21.9% 
from all 197 patients.  
Relatively agreed with these findings in Al-Nsour study where showed that the rectum 
cancer constituted 36.5 % and colon cancer 63.5 % from all CRC cases (Al-Nsour, 2014). 
Another previous study have provided relatively same results compared to the current 
study in Qiu and colleagues study where outlined that the colon cancer and rectal cancer 
accounted 77.9%, 22.1% respectively (Qiu et al., 2015). 
Contradicted with the study results, previous study was conducted in the South Korea 
which showed that the rectal cancer accounted slightly more than the half of all colorectal 
tumors about 51.8%, where as in this current study the rectal cancer accounted only 25.9% 
from all colorectal tumors (Kim et al., 2000).  
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Table (4.4) Distribution of the study cases according selected tumor characteristics 
  
 
 
 
 Socio-demographic factors No. of cases Percent 
1. Age at diagnosis group 
 <40 13 6.3  % 
40-49 33 15.6 % 
50-59 52 25.1 % 
60-69 63 30.4 % 
>=70 46 22.2 % 
Total 207 100  % 
2. Gender 
 Female  94 45.4 % 
Male 113 54.6 % 
Total 207 100  % 
3. Marital Status 
 Married 172 83.1 % 
unmarried 34 16.4 % 
unreported 1 0.5  % 
Total 207 100% 
4. Residency  
 North Gaza 34 16.4 % 
Gaza 77 37.2 % 
Gaza Center 29 14.0 % 
Khan Younis 40 19.3 % 
Rafah 27 13.0 % 
Total 207 100  % 
5. Work 
 Unemployed 16 7.7  % 
Employed 14 6.8  % 
Unreported 177 85.5%  
Total 207 100 % 
6. Education 
 BS.C 8 3.9 % 
Unreported 199 96.1% 
Total 207 100% 
The mean of age at diagnosis for the study population is 59.6 years. 
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4.1.3.5 Distant metastasis status 
      
According the study findings 78 cases out from 207 cases (37.7%) have metastasis to 
distant organs at time of diagnosis, and is added to them ten cases have developed distant 
metastasis during treatment journey to make the total number of distant metastatic cases 88 
cases with 42.5% from all study cases.  
Also study findings reveal that 65 cases out from 88 cases who have distant metastasis, 
have liver only metastasis, and is added to them 16 cases had liver metastasis concomitant 
with other metastasis. So the overall percentage of liver metastasis for CRC cases who 
were diagnosed in 2008-2010 with stage IV is 91.8% from all cases. While 4.5% from 
cases had lung only distant metastasis and 3.4% with brain only metastasis (Table 4.5).  
Previous study was conducted in USA showed that about 31% from distant metastasis are 
developed after CRC diagnosis, while 69% at time of diagnosis. It added that the liver is 
the most common site for metastasis with about 68.5% all of metastatic sites (Patanaphan 
et al., 1993). 
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Table (4.5) Distribution of CRC cases (2008-2010) according distant metastasis status 
 
 No. of cases % percent 
1. Metastatic status at diagnosis 
non metastatic case 115 55.6 % 
metastatic case 78 37.7 % 
Unknown 14 6.8 % 
Total 207 100 % 
2. Developing distant metastasis during treatment 
Yes 10 8.7 % 
No 105 91.3 % 
Total 115 100 % 
3. Distant metastasis to liver only 
Yes 65 73.8 % 
No 23 26.2 % 
Total 88 100 % 
4. Distant metastasis to liver concomitant with other mets.  
Yes 16 18 % 
No 72 82 % 
Total 88 100 % 
5. Distant metastasis to lung only 
Yes 4 4.5% 
No 84 95.6 % 
Total 88 100% 
6. Distant metastasis to brain only 
Yes 3 3.4% 
No 85 96.6% 
Total 88 100% 
 
4.1.4 Medical management of colorectal cancer in the Gaza Strip. 
4.1.4.1 Diagnostic process 
 Diagnostic delay 
Diagnosis delay was defined previously as the condition if the interval to diagnosis 
exceeds 3 months, where the reviewing of the medical records of the study cases shows 
that 121 medical records had precise information about time of signs and symptoms related 
to CRC were experienced by the study cases.  
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The study findings show 61.9% from the study cases were diagnosed within one month 
from initiation of signs and symptoms, 16.5% within one month to three months, and 
21.6% were diagnosed after three months (Table 4.6). 
 
Table (4.6): Distribution of the study cases according signs and symptoms at 
diagnosis. 
 
 No. of cases % percent 
1. The presence of signs and symptoms at time of diagnosis 
Yes 139 100% 
No 0 0% 
Total 139 100% 
2. Bleeding per rectum      
Yes 88 63.3% 
No 51 36.7% 
Total 139 100% 
3. Abdominal pain      
Yes 49 35.3% 
No 90 64.7% 
Total 139 100% 
4. Intestinal obstruction 
Yes 17 12.2% 
No 122 87.8% 
Total 139 100% 
5. Bowel habits changes diarrhea constipation 
Yes 22 15.8% 
No 117 84.2% 
Total 139 100% 
6. Anemia 
Yes 26 18.7% 
No 113 81.3% 
Total 139 100% 
7. Duration of signs and symptoms before diagnosis 
Less than one month 86 61.9% 
More 1 m up to 3 m 23 16.5% 
More than 3 months 30 21.6% 
Total 139 100% 
 
 Main Signs and symptoms related to CRC 
Data about the presence of signs and symptoms at time of diagnosis was found in 139 
medical records. These 139 patients (100%) presented with signs and symptoms at time of 
diagnosis. The researcher suggested that, it is directly refereed due to absence of CRC 
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screening programs in GS, and it is may indicated for low public awareness and concerns 
of CRC in GS.  
The most frequent signs and symptoms among the 139 patients are as the following: The 
commonest is bleeding per rectum with 63.3% from all patient, then abdominal pain with 
35.3%, then anemia 18.7%, followed by bowel habits changes (diarrhea/constipation) with 
15.9% and intestinal obstruction with  12.2 % from all patients (Table 4.6). 
The study findings agree with Macrae and colleagues study which showed that 34 % from 
CRC cases are presented with abdominal pain at time of diagnosis which accords with the 
study findings. While regarding bleeding per rectum, the current study showed results 
disagree with Macrae and colleagues study which outlined that only 37% of cases are 
presented bleeding per rectum. In the other hand, this current study showed slightly lower 
anemia percentage compared to the same study 18.7%, 23% respectively (Macrae et al., 
2016).  
Also another previous study conducted in China agreed in some signs and symptoms and 
disagreed with others. It showed similar findings regarding per bleeding rectum with 65 % 
where the current study records 63.3%. The same study disagreed regarding intestinal 
obstruction which showed only 5.2% have this signs from all cases which is lower than the 
current study ,while it showed higher percentage of bowel habits changes among the cases 
with 36% more than current study with about a double (Yuan et al, 2013).   
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Table (4.7): Distribution of the study cases according treatment process 
 
 No. of cases % percent 
1. The presence of signs and symptoms at time of diagnosis 
Yes 139 100% 
No 0 0% 
Total 139 100% 
2. Bleeding per rectum      
Yes 88 63.3% 
No 51 36.7% 
Total 139 100% 
3. Abdominal pain      
Yes 49 35.3% 
No 90 64.7% 
Total 139 100% 
4. Intestinal obstruction 
Yes 17 12.2% 
No 122 87.8% 
Total 139 100% 
5. Bowel habits changes diarrhea constipation 
Yes 22 15.8% 
No 117 84.2% 
Total 139 100% 
6. Anemia 
Yes 26 18.7% 
No 113 81.3% 
Total 139 100% 
7. Duration of signs and symptoms before diagnosis 
Less than one month 86 61.9% 
More 1 m up to 3 m 23 16.5% 
More than 3 months 30 21.6% 
Total 139 100% 
 
4.1.4.2 Treatment process 
4.1.4.2.1 Treatment types 
 
Stage at diagnosis is the main factor for defining the treatment model for CRC. As general 
the study finding show that 83% from cases underwent surgical intervention, 82.6% have 
chemotherapy, 16.4% have radiotherapy, and 38% had palliative care. 
Data analysis regarding the treatment types shows that 26 (13.70) underwent surgery only 
and those were diagnosed with stage 1, 24 (12.6%) cases have chemotherapy only, 105 
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 (55.5%) cases underwent surgery beside chemotherapy, 27 (14.2) cases underwent surgery 
beside the chemotherapy and radiotherapy as shown in table (4.7).   
 
4.1.4.2.2Treatment delay 
 Surgery delay 
 
Data about date of surgery is found in 156 medical records, where the data analysis shows 
that the mean for waiting time from date of confirmed diagnosis to surgery was 32 day (SD 
68.1), while more than 78% from patients who underwent surgery, the surgery was done in 
the first month of diagnosis and about half of them have the surgery within fourteen days 
from time of diagnosis. Regarding the surgery delay the study findings show that 21.8 % 
from the study cases have surgery delay where the surgery underwent after 31 days from 
date of confirmed diagnosis.  
 Chemotherapy delay 
 
About waiting time to the chemotherapy initiation after surgery only 52% from cases have 
chemotherapy within the first month from surgery, 23% within one month to two month, 
while about 25% time waiting for chemotherapy exceeded 3 months from date of surgery. 
This means that about quarter of the study cases have chemotherapy delay. 
These results are better than what shows in Chan and colleagues study which revealed that 
more than half of patients failed to have chemotherapy within the first two months from 
date of surgery. Study findings are on line with previous study results which was 
conducted in Jordan which showed that about 77.9% from CRC patients underwent 
surgery within the first month from the diagnosis (Al Nsour, 2014).  
 
4.1.4.2.3 Treatment places 
Regarding the main treating hospitals in GS, the study findings show that Al-Shifa hospital 
is the main hospital for 130 cases (62.8%), while 77 cases (37.2%) are treated at the 
European Gaza hospital.  
Regarding the surgery place, the study findings show that 79.1% from the cases who 
needed the surgery, have it inside GS, while 20.9 % outside GS. 
Regarding chemotherapy place, the studying findings show that about 75% from the cases 
who need the chemotherapy have it inside GS, while 25% have it outside GS. 
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In the other hand, the radiotherapy services are not available inside GS, so the patients who 
need the radiotherapy are referred abroad.      
 
4.1.5 The overall observed survival rate 
 
Previously in this study, the overall observed survival (OS) rate is defined as the 
percentage of people with a specific type and stage of cancer who have not died from any 
cause during a certain period of time after diagnosis. In this current study, OS rate was 
calculated for all study cases (207 CRC cases diagnosed at period 2008-2010) at different 
time periods from 1-years to 5-years as illustrated at table (4.7). The overall observed OS 
rate was calculated for each year regardless of any prognostic factors that may be affect on 
the survival rate such as stage at diagnosis, tumor grade, socio-demographic factors, or 
management related factors. The best survival rate is seen at the end of first year with 85%, 
and it gradually declines through years to reach the lowest survival rate at 5-years with 
45.1% as illustrated in table (4.7).  
Table (4.8) Calculation of observed overall survival rate for the entire study 
population 
 
Time 1-year 2-year 3-year 4-year 5-year 
Alive 171 142 127 116 94 
Dead 36 65 80 91 113 
Total 207 207 207 207 207 
Calculation 171/207*100 142/207*100 127/207*100 116/207*100 113/207*100 
Overall 
Survival rate 
82.6% 68.6% 61.4% 56% 45.1% 
 
This trend agrees with the majority of previous studies which showed that the survival 
rates decline dramatically through years from time of diagnosis (Al-Nsour, 2014; Yuan et 
al., 2013; Majek et al., 2012). Study findings showed that overall 5-years survival rate for 
colorectal cancer cases who were diagnosed at the period 2008-2010 and they were eligible 
for the study was 45.1%. Compared these results to other regions, shows that 5-years 
survival rate for CRC cases at GS was poorer than many countries in the world and better 
than few countries (Figure 4.1). In Jordan 5-years survival rate for colorectal cancer cases 
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was 57.7 % for CRC cases diagnosed at the period 2003-2007 (Al-Nsour, 2014). Previous 
study In Malaysia, revealed that 5-year survival rate was 59.1% (Hassan et al., 2016). In 
Iran, there were contraindicated studies, in Moradi and colleagues have showed that the 5-
years survival rate was 41% (Moradi et al., 2009), while where at another study 61% 
(Moghimi-Dehkordi et al., 2008).  
Compared with developed countries, the overall OS rate in GS is poorer than all the 
developed countries. As example the overall 5-year survival rate was 65.2% in USA 
(O’Connell et al., 2004), In Korea, 61 % (Kim, et al., 2000), In the Netherlands 52% (Van 
Steenbergen et al., 2010). 
CONCORD-2 study provided survival statistics regarding CRC for many countries and 
outlined that the 5-years survival rate for CRC cases who were diagnosed at period 2005-
2009 in Canada, Finland, the Netherlands, Norway, Sweden, and the USA was between 
62% to 65% (Allemani et al., 2015). Furthermore Organization for Economic Co-operation 
and Development-OECD (2015) have demonstrated that Korea and Israel have the best 
survival rates among OECD countries which reach over 70% (OECD, 2015). 
In the other hand study results are better than few countries in Asia like India, with rate 
31.2% (Moghimi-Dehkordi, and Safaee, 2012), While it is relatively similar to the overall 
5-year survival rate in Saudi Arabia which was 44.6% for the period 1994-2004 (Alsanea 
et al., 2015). 
 
4.2 Inferential analysis 
4.2.1 Observed survival estimates by using Kaplan-Meier method. 
4.2.1.1 Overall survival estimates 
The total number of the included cases in this current study is 207 CRC cases who were 
diagnosed at the period 2008-2010 and they met the inclusion criteria for the study (Table 
4.8). Each case was followed for complete five years in order to be able to estimate 5-years 
survival rate by using Kaplan-Meier methods. So cases who were diagnosed in 2008 
followed to end of 2012, cases were diagnosed in 2009 followed to end of 2013, while 
cases who were diagnosed in 2010 followed to end of 2014. As general the start time point 
for follow up was 1/1/2008 and end time and last contact with cases was 31/12/2014. 
Survival time was calculated by using Kaplan-Meier method by months and years for all 
study cases from date of diagnosis till date of death or censoring. By using the Kaplan-
Meier test, the 5-year survival rate for CRC patients was found about 45% as shown in 
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figure (4.2). While as shown in table (4.9) the mean survival time by months was 
37.1months (SE=1.65), and by years was 3.1 years (SE=0.15).  
These results relatively are lower than many countries over the world as literature shows 
such as previous study in Iran showed that the mean survival time for CRC cases was 56.5 
±1.9 months (Karimi, et al., 2011). While the current study results showed that median 
survival time was about four years, it also lower than median survival time in van Eeghen 
and Colleagues study (2015) which conducted in the Netherlands, where was 5.13 years 
(van Eeghen et al., 2015). 
 
Table (4.9): Kaplan-Meier survival analysis for all study cases/observed survival rate  
 
Time 1-year 2-year 3-year 4-year 5-year 
Alive 171 142 127 116 94 
Dead 36 65 80 91 113 
Total 207 207 207 207 207 
Calculation 171/207*100 142/207*100 127/207*100 116/207*100 113/207*100 
Overall 
Survival rate 
82.6% 68.6% 61.4% 56% 45.1% 
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Figure (4.2): Kaplan-Meier survival curve for all CRC cases included in the study 
(2008-2010) in GS. 
 
 
 
 
4.2.1.2 Disease Free Survival (DFS) estimates for non-metastatic cases 
 
DFS rate was determined for 113 cases who were diagnosed with all stages except stage IV 
and they have precise data about date of surgery, disease recurrence, and vital status 
information. As shown at table (4.8) the best DFS rate was at 1-year with 91%, while 5-
years DFS rate was 61% (Figure 4.3). These results were relatively low compared to many 
studies in the literature especially in developed countries. In Grande and colleagues study 
showed that 5-years DFS rate  was 76.7% in Italia (Grande et al., 2013). Another study 
conducted in the South Korea showed that 5-years DFS rate was 84.4% (Park et al., 1999). 
But the current study results showed DFS rate in GS was better than DFS rate in Iran 
where was about 57%  (Gunderson et al., 2008). 
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Figure (4.3): Kaplan-Meier curve for disease free survival estimates/non- metastatic 
cases 
 
 
 
4.2.1.3 Progression Free Survival (PFS) estimates for metastatic cases 
 
Progression Free Survival (PFS) rate was calculated for metastatic cases which were 88 
cases and they have enough data about date of start chemotherapy, date of disease 
progression or the second chemotherapy cycle, and the vital status data.  
PFS rate at 1-year survival rate was 54% and 5-years PFS rate was 28% as shown in table 
(4.9) and illustrated in figure (4.4). 
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Figure (4.4): Kaplan-Meier curve for Progression free survival estimates of 
metastatic cases 
 
4.2.2 Effect of patient related factors on overall survival rate 
4.2.2.1 Survival analysis according age group 
 
The study cases are divided into three groups according to age at diagnosis: age group-1 
<50 years, age group-2 (50-69 years), and age group-3 ≥ 70 years (Figure 4.1).  
Kaplan-Meier test by age group shows that the age group-1 have the best mean survival 
time among the three age groups with about 43 months followed by age group-2 with 
survival months means about 36.3 months, while the poorest mean survival time is among 
age group-3 with 32.9 months (Table 4.10).  
These survival differences are not statistically significant, but as the overall young age at 
diagnosis correlate with better survival which is clear in figure (4.5). The literature shows 
contradicted results for different previous studies. From one hand, there are various studies 
agreed with current study results where have showed that young age at time of diagnosis 
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correlated with better survival rate (Jiang et al., 2016; McKay et al., 2014; Steele et al., 
2014; Kemppainen et al., 1995).  
In the other hand, the current study results contraindicate with results in previous studies 
such as in Chan and colleagues study where showed that CRC patients less than 40 years 
olds had poorer survival rate compared with patients >40 years old (p < 0.05) (Chan et al, 
2010). Also Fu et and colleagues study shows contraindicated results compared with this 
current study results, where outlined that CRC patients who their age below 35 years old 
had lower overall survival rate than older patients (Fu et al., 2014). In addition to that 
previous study In China, showed that there were statistically differences in survival rate 
among different age group of patients. It showed that age group (60–74) had better survival 
rate (Yuan et al., 2013). That disagreed with current study results but it agreed with that the 
poorest survival rate was among age group <75 years old. 
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Table (4.10): Kaplan-Meier survival analysis by selected patient related factors 
 
Variable Subgroups Total no. Mean 
survival 
time 
Median 
survival 
time 
5-years 
survival  
rate 
(%) 
Log rank test 
χ2 Sig. 
Age group <50 49 42.9  55 2.91 0.233 
50-69 112 36.2 37.5 43 
≥70 46 32.8 29.3 40 
Gender Male 113 38.8 56.0 50 1.24 0.265 
Female 94 35.0 33.2 40 
Marital Status Married 172 37.8 47.8 48 .41 0.518 
Unmarried 34 32.4 32.4 41 
Residency North Gaza 34 39.3 37.8 58 3.25 0.516 
Gaza 79 37.8 34.4 42 
Mid Zone 29 38.5 28.8 50 
Khan Younis 41 32.0 52.5 37 
Rafah 24 38.3 37.8 53 
Co-morbidity 
Status 
YES 66 28.6 20.9 35 4.23 0.040* 
NO 89 38.3 39.9 43 
Family History of 
cancer 
YES 34 29.9 22.0 36 1.156 0.282 
NO 97 37.3 41.5 43 
classification of 
BMI 
Normal weight 
BMI <25 
kg/m2 
66 33.7 
30.4 
42 4.055 0.044* 
Overweight/ 
Obese 
BMI ≥25 
kg/m2 
88 41.4 
- 
58 
Smoking Non-Smoker 88 40.0 - 53 9.204 0.002* 
Smoker 56 28.0 21.3 30 
*Statically significant 
65 
 
Figure (4.5): Kaplan-Meier survival curves for cases by Age group
 
4.2.2.2 Survival analysis according Gender 
Kaplan-Meier test is used to analyze the survival rates for CRC cases according gender. 
The test result shows that the male cases have slightly longer survival time than female 
cases as shown at table (4.10) and figure (4.6).The mean survival time for male cases was 
about 39 months, while for female was 35 months.  
Theses Survival differences between male and female cases are not statically significant 
(p-value =0256). Even though these survival differences between the female cases and the 
male cases may referred to many factors such as the culturally barriers for female to seek 
medical help for bowel diseases in early stages, and the poor health awareness among 
female rather than male cases in GS. 
These findings disagreed with many global studies which show that the female cases have 
better survival rates from CRC than the male cases. For example, previous study conducted 
in Jordan showed slightly higher survival rates among females even though these finding 
were not statically significant (p-value=0.1698) (Al-Nsour, 2014). Another study 
conducted in China showed that there were no statically significant survival differences 
between male and female patients, but in the opposite of this current study the female 
patients in China had better survival rate that male patient about 2 %. (Yuan et al., 2013). 
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In Korea, female patients had 5-years survival rate about 3% better than male cases (P-
value=0.26) (Kim et al., 2000).  
Figure (4.6): Kaplan-Meier survival curves for cases by gender
 
4.2.2.3 Survival analysis according to Marital Status 
 
Kaplan-Meier method is used to investigate the impact of marital status at diagnosis on 
survival rate from CRC. As shown in figure (4.7) the survival benefits go to the married 
cases, the mean survival time by months for the married cases was 37.8 months (3.2 years), 
while for the unmarried cases survival 32.5 months (2.7 years).  
These survival differences are not statistically significant (P-value =0.518). These findings 
are compatible with many previous studies which showed that the married cases have 
better survival than the unmarried cases (Qingguo et al., 2015; Shi et al., 2016; Wang et al., 
2011).  
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The researcher suggested that the married patients have more chance to discover CRC as 
early as possible, seek medical help quickly, beside the emotional and psycho-social 
support for the married cases rather than unmarried. 
 
Figure (4.7): Kaplan-Meier survival curve by Marital Status 
 
4.2.2.4 Survival analysis according to place of residency for all study cases 
  
The study cases are divided by place of residency to five groups according GG. Then 
Kaplan-Meier test is used to analyze the survival data for the study cases according place 
of residency. As illustrated in table (4.10) the cases who are resident in North Gaza have 
better mean survival time with 39 months while the least mean survival time among the 
cases from Khan-Younis Governorate.  
These Survival differences between GG are not statistically significant. In line with other 
previous studies, many studies showed survival differences between the same population 
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according their place of residency within the country borders. In Al-Nsour study which 
was conducted in Jordan outlined that the cases who were living in the central part of 
Jordan have the highest survival rate compared to the cases who were living in the northern 
and southern regions (Al-Nsour, 2014). 
 
Figure (4.8) Kaplan-Meier survival curves by place of residency 
 
 
4.2.2.5 Survival analysis according co-morbidity status of cases. 
 
Kaplan-Meier test is used to analyze of co-morbidity impact on survival rate among CRC 
cases. Test results show statistically significant survival differences between the cases with 
co-morbid disease and the cases without co-morbid diseases where the P-value is 0.040 
and the cases without co-morbidity have mean survival time more than the cases with co-
morbidity with about 8 months as shown in table (4.10) and figure (4.9). 
69 
 
 In general, the majority of previous studies show that the cancer patients with co-
morbidity have poorer survival rates than those without co-morbidity (Sogaard et al., 
2013). Previous meta-analysis study has showed that CRC patients with diabetes have 
poorer survival rate than those without diabetes (Mills et al., 2013). Else previous study 
revealed that patients who had co-morbidity before time of CRC diagnosis had poorer 
survival rate than those without co-morbidity (Shack et al., 2010). 
 
Figure (4.9) Kaplan-Meier survival curves by co-morbidity status 
 
 
 
4.2.2.6 Survival analysis according Patient’s family history of cancer 
Kaplan-Meier method is used in order to analyze the impact of patient’s family history of 
cancer on survival data from CRC and as illustrated in table (4.10) the cases with negative 
family history of cancer have mean survival time (29.9 months) better than the cases with 
positive family history of cancer (figure 4.10). 
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These survival differences are not statically significant where the log rank test shows the P-
value= 0.282.  
Contraindicated with these findings, previous study was conducted in China have showed 
that the patient with positive history family cancer have better survival rate than patients 
with negative family history of cancer. (Yuan et al., 2013). 
 
Figure (4.10) Kaplan-Meier survival curves for cases by patient family history of 
cancer 
 
 
4.2.2.7 Survival analysis according Body Mass Index-BMI of the cases. 
Kaplan-Meier method was used in order to analyze the impact of obesity (Based on BMI 
scale) on the survival data for the study cases. The entire study population was divided 
according BMI to two subgroups. The first group is CRC cases who were diagnosed with 
BMI <25 kg/m2 (Normal weight), while the second group is those who were diagnosed 
with BMI ≥25 kg/m2 (Over weight/Obese).  
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As shown in table (4.10) mean survival time for the cases with normal weight at time of 
diagnosis (33.4 months) is poorer than the mean survival time for the cases with 
overweight/obesity at time of diagnosis (41.4 months).  
These survival differences are statically significant, where the P-value was 0.044 according 
the log rank test result. These results accord with Hines and colleagues study which was 
conducted in USA, where showed that the African American who were overweight/obese 
have better survival rates than underweight cases.  
In the other hand study results disagreed with many previous studies which showed that 
overweight and obesity associated with poorer survival rate compared with normal weight 
cases (Murphy et al., 2000; Campbell et al., 2011; Hall, 2006; Lee et al., 2015b).  
The researcher suggested that the differences between the current study and the other 
studies, due to the majority of CRC cases in GS diagnosed with advanced stages.  
    
Figure (4.11): Kaplan-Meier survival curves by Body Mass Index-BMI
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4.2.2.8 Survival analysis according smoking status of the cases 
Kaplan-Meier test is used to analyze the effect of smoking on the survival data for the 
study cases and as illustrated in table (4.10) the non-smoker cases have mean survival 
about 40 months (SE: 2.543) which is better than smoker cases where the mean survival 
time is 28 months (SE: 3.228).  
These survival differences are statically significant (P-value: 0.002). These results accord 
with many previous studies which showed that the smoking as general decrease the 
chances to survive longer from CRC, as result for this the non-smokers cases have better 
mean survival time (Walter et al., 2014; Yang et al., 2015; Walter et al., 2015; Boyle et al., 
2013). 
 
 
Figure (4.12): Kaplan-Meier survival curves by smoking status 
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4.2.3 The effect of tumor related factors on survival estimates 
4.2.3.1 Survival analysis according stage at diagnosis 
Kaplan-Meier test was used to analyze the survival data for cases according CRC stage at 
diagnosis. As shown in table (4.11) mean survival time by months for cases with stages I, 
II, III, and IV was 60, 53.6, 39.5, and18.7 respectively. The best mean survival time was 
for cases who diagnosed with stage I, while the worst mean survival time was for cases 
diagnosed with stage IV. These survival differences are statistically significant (P-value: 
0.001). These finding accord with the majority of previous studies where outlined that 
stage at diagnosis has statically significant effect on survival time, and added that survival 
time for low stages was better than survival time for advanced stages (Fu et al., 2014; Yuan 
et al., 2013; O’Connell et al., 2004; Al-Nsour, 2014).    
  
 
Figure (4.13): Kaplan-Meier survival curve according satge at diagnosis. 
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Table (4.11): Kaplan-Meier survival analysis according selected tumor related factors 
 
4.2.3.2 Survival analysis according tumor grade 
Kaplan-Meier test was used to analyze impact of tumor grade on survival from CRC. 
Results showed statistically significant survival differences based on tumor grade (P-
value= 0.041). Grade-1 and Grade-2 had the best mean survival by months about 41, 38.2 
Variable Subgroups 
Total 
no. 
Mean 
survival 
time by 
months 
Median 
survival 
time by 
months 
5-years 
survival 
rate 
(%) 
Log Rank 
χ2 
p-
value 
Stage at 
Diagnosis 
Stage  I 6 60.0 60 100 
93.6 0.001* 
Stage II 67 53.6 43.8 78 
Stage III 40 39.5 34.4 40 
Stage IV 77 18.7 9.8 16 
Grade 
Grade 1 14 40.9 47.8 50 
0.745 0.041* Grade 2 140 38.2 47.8 46 
Grade 3 29 31.8 26.0 41 
Tumor 
site 
Rt. Colon 43 25.2 12.0 32 
11.16 0.004* Lt. colon 103 40.2 60.0 48 
Rectum 51 40.7 51.8 50 
Sites of 
Distant 
Metastasis 
Liver only 
metastasis 
62 21.7 11.0 19 
4.730 0.094 
Liver mets. 
concomitant 
with other 
mets. 
14 16.1 10.3 8 
Other distant  
metastasis 
8 9.0 5.2 0 
*Statically significant 
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respectively while Grade-3 and Grade-4 had the worst mean survival by months about 32 
as shown on table(4.11). These findings were agreed with many previous studies findings 
which showed that low tumor grade is related with better survival time from CRC (Yuan et 
al., 2013; O’Connell et al., 2004; Al-Nsour, 2014). 
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Figure (4.14): Kaplan-Meier survival curves according tumor grade 
 
 
 
4.2.3.3 Survival analysis according tumor site. 
Kaplan-Meier test showed statistical differences between cases according tumor site, 
where tumors developed in rectum correlated with the best mean survival time followed by 
tumors developed in Lt. Colon. While tumors developed in Rt. Colon had the poorest mean 
survival time as illustrated at table (4.11).  Figure (4.16) shows Kaplan-Meier survival 
curves according tumor site.  
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Figure (4.15): Kaplan-Meier survival curves according tumor site 
 
4.2.3.4 Survival analysis according distant metastasis sites 
 
Kaplan-Meier test was used to analyze the impact of different metastasis sites on survival 
data for metastatic cases. Metastasis sites were divided into three subgroups as the follow: 
Liver only metastasis, Liver mets. Concomitant with other mets., and other distant  
metastasis as shown in table (4.11). Test results showed that metastatic cases with liver 
only metastasis had slightly longer survival time than other metastatic cases (Figure 4.17), 
but these survival differences were not statistically significant (P-value= 0.094).   
 
 
 
 
 
 
  
78 
 
Figure (4.16): Kaplan-Meier survival curves according distant metastasis sites 
 
 
4.2.4 The effect of healthcare related factors on survival estimates. 
4.2.4.1 Survival analysis according main treating hospital. 
 
As shown in table (4.12) there were no statically differences on survival data between 
cases based on their main hospital. Even though cases who were treated at Al-Shifa 
hospital had slightly longer survival time than cases who were treated at EGH with about 2 
months. The researcher suppose the absence of survival differences as shown in figure 
(4.17) between the two hospitals due to the two hospital are governmental hospitals and 
relatively they provided the same services.   
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Table (4.12): Kaplan-Meier survival analysis according healthcare related factors. 
 
 
 
 
 
 
  
Variable Subgroups Total 
no. 
 
Mean 
survival 
time by 
months 
 
Median 
survival 
time by 
months 
5-years 
survival 
rate (%) 
Log Rank 
χ2 Sig. 
Main Hospital EGH Hospital 77 35.7 41.500 44 
0.830 0.362 
Al-Shifa Hospital 130 37.9 47.333 46 
Diagnostic  
Delay 
Delayed  (>3 months) 30 41.7 - 54 
0.739 0.390 
No delay (<3 months) 109 37.9 51.3 48 
Treatment 
Type 
Surgery only 26 41.7 - 58 
17.22 
0.001* 
 
Chemo. only 24 22.2 14.200 18 
Surgery + Chemo. 105 40.3 54.267 48 
Surgery+Chemo.+Radio 27 42.3 - 50 
Surgery Place Inside Gaza Strip 124 42.5 60.0 52 
1.646 0.200 
Outside Gaza Strip 33 34.3 28.8 42 
Surgery Delay Delayed surgery(>31days) 34 37.2 37.8 39 
2.682 0.101 
No delay(<31days) 122 42.1 49.2 55 
Chemotherapy 
place 
Inside Gaza Strip 117 38.8 48.1 42 
3.520 0.061 
Outside Gaza Strip 33 28.3 21.2 28 
Chemotherapy 
delay 
Delayed Chemotherapy 
(>3m after surgery) 
30 38.322 
42.1 42 
0.098 0.754 
No Delay (< 3m after 
surgery) 
93 41.5 
53.2 45 
 *statically significant   
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Figure (4.17): Kaplan-Meier survival curve according main treating hospital for cases  
 
 
4.2.4.2 Survival analysis according diagnostic delay. 
 
Information about signs and symptoms which related to CRC starting date was found in 
139 medical records out from 207 records. Thirty cases from the 139 cases have diagnostic 
delay while 109 were diagnosed within one month. Kaplan-Meier test is used to analyze 
effect of diagnostic delay on survival data, where the log rank test results shows that there 
were no statically significant differences between the subgroups (P-value= 0.390). 
However patients who had delay in diagnosis had slightly better mean survival time than 
those without delay in diagnosis with about four months as shown in (figure 18). These 
results accord with many previous studies. For example, study conducted in Australia 
showed that delayed diagnosis had not statically significant affect on survival from 
colorectal cancer, and added that short interval for diagnosis was associated with worse 
survival (Pita-Fernández et al., 2016)  
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Figure (4.18): Kaplan-Meier survival curves  for cases according diagnostic delay   
 
 
4.2.4.3 Survival analysis according the main treatment type. 
 
Kaplan-Meier test was used to analyze the effect of treatment types and combination of 
them on the survival data for CRC cases. Table (4.7) showed the distribution of study cases 
according the received treatment type. The test results have showed statically significant 
survival differences between the cases groups (P-value= 0.001) as illustrated in table 
(4.12). Where the mean survival time for cases who received the surgical intervention, 
chemotherapy and radiotherapy is the best with 42.3 months while the worst survival time 
for cases who received only chemotherapy.  
The same results are found in Wiegering and colleagues study, where they have 
demonstrated that a combination between treatment (surgery, chemotherapy, and 
radiotherapy) is associated with better overall survival rate for CRC patient with all stages 
(Wiegering et al., 2014). The surgical resection remains the only hope for complete cure 
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from CRC and one of the most common palliation methods in the patients with incurable 
CRC (Shankar et al., 1999). Xu and colleagues study revealed that the surgical resection of 
primary tumors associated with better survival rate even in cases even with unresectable 
stage IV CRC (Xu et al., 2015).   
Figure (4.19): Kaplan-Meier survival curves for study cases by treatment type. 
 
 
4.1.4.4 Survival analysis according surgical intervention place. 
Kaplan-Meier test was used to explore the effect of the surgical place on survival data for 
cases who were underwent surgical resection (4.12). The log rank test shows no statically 
significant differences between cases who had surgery inside GS and cases who had 
surgery outside GS. However, cases who were underwent surgery inside GS had slightly 
better mean survival time with about 8 months (Figure 4.20). Theses difference may be 
referred due to the most of cases who had surgery outside GS were with advance stage of 
CRC.  
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Figure (4.20): Kaplan-Meier survival curves for cases according surgical intervention 
place. 
 
 
4.2.4.5 Survival analysis according surgery delay. 
Kaplan-Meier test is used to analyze the effect of surgery delay on survival data for the 
study cases who underwent surgical intervention. The cases were divided into three 
subgroups according waiting time for surgery as shown in table (4.7). The log rank test 
shows no statically significant survival differences between the study cases according 
waiting time for surgery (P-value=0.101). However, short time for surgery associated with 
better survival rates, whereas cases who were underwent surgery before 14 day since 
confirmed diagnosis have the best survival time with mean 44.3 while cases with delayed 
surgery (>31 days after confirmed diagnosis) have the worst survival time with mean 37.2 
as shown in table (4.12) and illustrated in figure (4.21). Agreed with the researcher 
findings in previous study conducted in Canada where outlined that there are no significant 
relationship between the surgery delay and the survival from CRC (Simunovic et al., 
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2009). Another previous study showed that treatment delay is not associated with poor 
survival of CRC patients and reasonable surgery delay dose not worse the survival rate 
where it permits more scheduling flexibility and proper evaluation of the condition (Amri 
et al., 2014).   
 
Figure (4.21): Kaplan-Meier survival curves for cases according surgery delay 
 
4.2.4.6 Survival analysis according chemotherapy place. 
 
Kaplan-Meier test is used to explore the impact of chemotherapy place on survival data for 
the study cases who need the chemotherapy (Table 4.12). According the log rank test 
results, there are no statically significant differences in survival data between the study 
cases who were treated with chemotherapy inside GS or outside GS (P-value = 0.61). 
However, cases who were treated outside GS had poorer survival time than the study who 
were treated inside GS. The researcher suggested these differences may be due to most of 
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cases who treated outside GS were with more advance stages and chemotherapy drugs for 
these advance stages were not available inside GS in most of time. 
 
Figure (4.22): Kaplan-Meier survival curves for cases according chemotherapy place 
 
4.2.4.7 Survival analysis according chemotherapy delay 
 
Kaplan-Meier test is used to examine the impact of chemotherapy delay on survival data 
for cases who need the chemotherapy cycles. The cases that need the chemotherapy are 
divided into two subgroups in term of chemotherapy. As shown in table (4.12), there are 
thirty cases with delayed chemotherapy (>3months after surgery), and 93 cases have not 
delayed chemotherapy. The log rank test shows no statically significant survival 
differences between the two subgroups (P-value= 0.754). However, the cases without 
chemotherapy delay had slightly better survival time than cases with delayed 
chemotherapy with about 3 months. In line with the literature, Xu and colleagues study 
agrees with the researcher findings where shows that the chemotherapy delay associated 
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with poorer survival rate but it showed statically significant association (P-value <0.001) 
(Xu et al., 2014). Previous systematic review and meta-analysis study demonstrated that 
longer time to chemotherapy is associated with worse overall survival rate (Biagi et al., 
2011). Another pervious study conducted in USA showed the same results where the 
delayed chemotherapy correlated with poorer survival rate (Bayraktar et al., 2011). The 
researcher supposes that the current result is not statically significant due to small size of 
study sample beside the effect of missing data in the medical records which were the main 
source of data.   
 
   Figure (4.23): Kaplan-Meier survival curves for cases according chemo-therapy 
delay
 
 
4.2.5 Cox Regression survival analysis  
Cox regression survival analysis is conducted to explore the independent effect of the 
different study variable on the survival rates from CRC. Table (4.13) illustrates the test 
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results for each entered factors. From the analyzed factors, only three factors have 
statically significant effect which are stage at diagnosis (P-value<0.001, 95% CI 2.673-
9.034), Co-morbidity status (P-value=0.031, 95%CI0.434-0.962) and tumor site (P-value 
0.018, 95%CI, 0.373) as shown in the table (4.13).The hazard ratio for co-morbidity 
(HR=0.646) which means that the risk for death decreased by 36% if the patient had not 
co-morbidity. The study results accord with many previous studies where showed the same 
results. Malaysian study conducted Cox regression survival analysis of CRC illustrated that 
staging at diagnosis was the prognostic factor with significant effect (p<0.001). These 
results agreed with the current study result (Suan et al, 2016). The multivariate analysis 
results in Yuan and colleagues study showed that only the TNM staging system had a 
statistically significant (P < 0.0001) effect on CRC  patients survival when all the study 
variables were included in the analysis (Yuan et al., 2013). In Jordan, previous study 
illustrated that the Cox regression analysis of prognostic factors of CRC showed more 
prognostic factors had statically significant effect on CRC which were  age, place of 
residency, extent of disease, and morphology  (Al-Nsour, 2014). Else five studies from 
different countries showed that stage at diagnosis had statically significant effect on CRC 
survival by using the Cox regression analysis (Mehrkhani et al., 2009; Al-Shamsi et al., 
2011; Park et al., 1999; Yeole et al., 2001; Ghazali et al., 2010). The five studies showed 
site of tumor lost its significant effect in the multivariate analysis while the co-morbidity 
status was not studied in these studies.     
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Table (4.13): Cox regression survival analysis of colorectal cancer in the Gaza Strip 
(2008-2010) 
 
 
 
 
  
Variable Hazard ratio 
95.0% CI for Exp(B) P-value  
Lower Upper 
Gender 1.259 0.880 1.802 0.208 
Age 1.009 0.996 1.023 0.188 
Marital Status 0.858 0.502 1.466 0.575 
Residency 1.001 0.856 1.171 0.991 
Family History of cancer 0.582 0.291 1.165 0.127 
Obesity status 0.518 0.266 1.010 0.054 
Smoking 1.516 0.826 2.782 0.179 
Co-morbidity Status 0.646 0.434 0.962 0.031* 
Tumor site 0.584 0.373 0.912 0.018* 
Grade 1.051 0.442 2.501 0.910 
Stage at diagnosis 4.914 2.673 9.034 <0.001* 
Histological Type 2.917 0.743 11.456 0.125 
Main hospital 1.287 0.202 8.210 0.789 
Chemotherapy Place 0.721 0.240 2.172 0.562 
Surgery place 1.798 0.605 5.345 0.291 
Radiotherapy place 0.474 0.055 4.083 0.497 
Treatment type 0.924 0.822 1.039 0.186 
Surgery delay 1.356 1.010 1.821 0.143 
Chemotherapy delay 1.154 0.854 1.558 0.351 
*Statically significant  
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Chapter (5) Conclusion and Recommendation  
5.1 Conclusion  
This study is conducted to explore the observed survival rate for CRC cases, and to 
investigate main factors may relate with CRC prognosis and the survival in GS at the 
period between (2008- 2010). The study defines three main groups of factors are suspected 
to have an effect on CRC prognosis and the survival rates. The first group is patient related 
factors which includes factors such as age at diagnosis, gender, marital status, and health 
related behaviors, the second group is the tumor related factors which includes factors such 
as histological type, tumor grade, stage at diagnosis, and tumor site, while the third group 
is healthcare related factors which is divided into two constructs: the first construct is 
diagnostic related factors which include two factors, Diagnostic delay and Signs and 
symptoms while the second construct is treatment related factors which include the factors, 
treatment delay, treatment types, and treatment places.   
The researcher used self-constructed data abstract sheet to collect data from the medical 
records which is considered the main source for data in this current study. A total of 207 
cases were enrolled after exclusion of some cases for various causes.  
In this current study, the Kaplan-Meier method is used to conduct the survival analysis for 
the study cases and to determine the overall survival rates. A univariate analysis was 
conducted to show impact of main study variables on the survival data such as stage at 
diagnosis, treatment type, and place of treatment. Also the log rank test was used to 
estimate difference between the groups. The researcher considered the variable to have a 
significant effect if the P-value ≤ 0.05, with 95% confidence interval. Also Cox-regression 
analysis is conducted to verify how far these differences between groups are statistically 
significant (P-value ≤ 0.05). 
One of the main obstacles was faced the researcher is incomplete and missing data in the 
medical records. So factors such as education level and occupation types were not studied 
due to absences of information in the medical records.  
Study findings showed that the mean of age at diagnosis for the entire study population 
was 59.6 years, and more than two third of cases occurred after age 50 with 77.7% from all 
cases. 54.6% from cases were male and 45.6% female. Regarding tumor characteristics 
adenocarcinomas (Non-mucinous) accounted 86.7% from histological type. More than two 
third of cases diagnosed with low grade tumor (grades 1+2), while more than the half of 
patients (61.6%) were diagnosed with advanced stages (III + IV). Left-sided colon is the 
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most common site for developing CRC with 52.3% of all cases. It followed with rectal 
cancer with 25.9%, While Right-sided colon accounted only 21.9%. 
The study results reveal that all of the study cases were presented with signs and symptoms 
at time of diagnosis, mainly due to absent of CRC screening program in GS. The main and 
symptoms are bleeding per rectum with 63.3% from all cases, then abdominal pain with 
35.3%, then anemia 18.7%, followed by bowel habits changes (diarrhea/constipation) with 
15.9% and intestinal obstruction with  12.2 % from all cases. Furthermore around 21% 
from the cases are diagnosed after 3 months from onset of signs and symptoms. 
Regarding the treatment of CRC in GS, the study finding show that about 13.70 underwent 
surgery, 12.6% cases have chemotherapy only, 55.5% cases underwent surgery beside 
chemotherapy, 27 (14.2) cases underwent surgery beside the chemotherapy and 
radiotherapy as shown in table have chemotherapy delay and surgery delay  
The survival analysis for 5-years follow up showed that the 5-years overall survival rate, 
disease free survival rate, progression free survival rate were 45.1%, 61%, and 28% 
respectively. These rates are considered very poor compared to developed countries which 
reach in many counties the ends of 60%. However, 5-years survival rate in GS was in line 
with survival rates in the neighbor countries such as Jordan and Saudi Arabia. The 
univariate analysis (Log Rank test) shows that the factors (Co-morbidity, obesity status, 
smoking, stage at diagnosis, tumor site, treatment type) were statically significant affect on 
the survival rate of CRC. While Cox regression survival analysis showed that only three 
factors prognostic factors had statically significant effect which were stage at diagnosis (P-
value<0.001, 95% CI 2.673-9.034), Co-morbidity status (P-value=0.031,95% CI0.434-
0.962)  and tumor site (P-value0.018,95%CI, 0.373). 
The survival figures show that the conditions such as the non-smoker, males, and married 
have better survival figures than others but without statically significant differences.   
The study provides the baseline of the survival data regarding CRC in GS, and the study 
findings need immediate actions to enhance the prognosis of CRC in GS and improve the 
quality of life of CRC survivors by discovering the cases early as possible and decrease the 
rates of patients who are diagnosed with late stages.  
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5.2 Recommendation 
5.2.1 The study Recommendation 
1. An urgent need for a national CRC screening program and launch national 
campaigns for increasing the public and official awareness regarding CRC. 
2. Providing GS hospitals with missing cancer services and new treatment models will 
contribute to enhance the overall survival rate 
3. Develop appropriate protocols and guidelines for documentation of the medical 
records and staging system for cancer diseases. 
4. Empowering the national center for cancer registry, in order to improve and 
promote completeness and quality of the recorded data. 
5.  Empowering the archiving system of the medical records to decrease the missed 
records.  
5.2.2 Recommendation for further research 
1- Conduct research studies to explore the main risk factors for developing CRC in 
GS. 
 
2- Carry out additional research studies to confirm the current results in large sample 
at national level including cases from West bank and for longer period. Beside that 
including other prognostic factors such as status of resection and serum CEA level.  
 
3- Conduct other research studies to analyze the survival rates from other common 
cancer in GS. 
 
4- Conduct economical studies concerning cancer services in the Gaza Strip.  
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Annex (1): Palestine map 
 
 
Source: (PCBS, 2015) 
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Annex (2): Gaza strip map 
 
 
 
 
Source: (Palestine question and answer, 2015)  
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Annex (3): A diagram of normal colon and rectum anatomy  
 
 
 
 
 
 
 
 
Source: (Mayo clinic, 2017) 
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Annex (4): Top Five Cancer among Gaza Strip population at period (2009-2014) 
 
 
 
 Type of cancer Cases No. % of all cancers 
1 Breast Cancer 1283 18.1 
2 Colorectal Cancer 709 10 
3 Lung Cancer 522 7.3 
4 Leukemia Cancer 490 6.9 
5 Lymphoma Cancer 409 5.8 
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Annex (5): Global survival difference in 5-years survival rate from CRC compared to 
the current study result (Gaza Strip) 
 
Source: Data retrieved from CONCORD-2 study, and the current study result regarding 
GS, while the figure is self-constructed.  
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Annex (6): An official letter of approval from the Helsinki Committee in the Gaza 
Strip 
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Annex (7): Official letter from Al Quds University to the Ministry of Health  
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Annex (8): Official approval letter from Ministry of Health  
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Annex (9): Inclusion and exclusion process for cases of the study population  
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Annex (10): The main steps for data collection with detailed information. 
 The First Step: At start, the researcher got on a list for colorectal cancer cases who 
were diagnosed in the period (2008-2010) from PCR which contained 255 cases. Each 
case was defined with full name, ID no., and date of diagnosis. The list was reviewed 
for repeated cases and validity of ID no. The researcher found two repeated cases (were 
removed from the list) and 55 cases with wrong ID number. But by use of Palestinian 
civilian record version-2009 the ID numbers were corrected except 3 cases. (Theses 3 
cases removed from the list). Annex (7) explains selection of cases in detail and causes 
for exclusion some of cases.  
 The Second Step: In parallel with first step the researcher reviewed all 
histopathological reports which were done at the period 2008-2010 in Al-Shifa hospital, 
the reports were not computerized, so it was hard to access the CRC cases. So the 
researcher asked for help from team of three nurses who trained on reviewing 
histopathological report and help from histopathological team. About 3000 
histopathological report were reviewed to find all cases had colorectal carcinomas 
biopsies in the period 2008-2010. As result of this reviewing, the researcher found 98 
cases with colorectal carcinomas. Matching these cases with the main list from cancer 
registry, eleven cases were not listed in the list, so they added to the list and other 
repeated cases were removed. 
 The third step: In EGH, Information technology unit has records for each case 
treated in the hospital. The researcher asked IT unit for list of patients which were 
defined with full name and ICD-10 (C18: colon cancer, C19: recto-sigmoid junction, 
C20: rectum cancer, C21: anal canal). IT unit supplied the researcher a list containing 
114 cases. This list was matched with main list to remove the repeated cases. Finally 75 
cases were not listed at main list (Cancer registry list), but when the researcher reviewed 
the medical records for these 75 cases found the majority of medical records had other 
diagnosis rather than which were recorded in IT unit and coded with ICD-10 except 7 
cases found with correct diagnosis comparable to recorded ICD-10. These cases were 
included in the study.  
 The fourth step: The researcher obtained vital status for cases listed for the study 
to know the location of medical records for each case, from Births and Deaths 
Directorate in MOH. As showed at tables (3.1) there were four places for the medical 
records for cases and the researcher began with cases in oncology outpatient clinic 
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archive in SPH and finished with cases in the central archive in MOH. All medical 
records were reviewed carefully to complete abstract sheet items  and needed 
information for the study such as present health status of patient, medical history, date 
of confirmed diagnosis (Histopathological report) histological type, tumor site, stage at 
diagnosis, signs and symptoms and duration before date of confirmed diagnosis, 
treatment information, type of treatment, place of treatment and others. TNM staging at 
diagnosis as described in table (2.1) was not available in the majority of medical 
records, so the researcher with kind help from supervisor (supervisor is oncologist and 
director of oncology department of Al-Shifa hospital) assigned the TNM staging for all 
cases as possible as information were present about tumor size, nodal status, and 
metastatic status.  
 The fifth step: As overall the main list of cases contained 262 cases. At time of 
finishing all available medical records, found that 55 cases out from 262 cases their 
medical records were not available in the four places of medical records stores. So they 
were excluded, the final number for eligible cases and included in the study was 207. 
The excluded 55 cases who had not medical records, the researcher went to cancer 
registry and asked him if there are any additional information about these cases 
especially date of confirmed diagnosis. Cancer registry has the date of confirmed 
diagnosis for these 55 cases were recorded in the cancer registry but it was the same 
date of death of the cases. Cancer registry justified that by that they did not find the 
medical records for these cases and they took information about cause of death from 
death certificate for cases. Regarding this current study, case without correct date of 
confirmed diagnosis was not eligible for the study.  
 The sixth step: prepared and organized all completed abstract sheet for 207 
eligible cases for entering in SPSS program version-22. 
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Annex (11): Data abstract sheet 
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 تحليل معدلات البقاء على قيد الحياة لدى مرضى سرطان القولون والمستقيم  في قطاع غزة.
 اعداد الباحث/ مراد بشير درويش الرن 
 د. خالد عطا ثابت / إشراف
 ملخص الدراسة: 
 مقدمة
ٌشهد قطاع غزة تحولا وبائٌا ٌتمثل فً زٌادة عبء الامراض الغٌر المعدٌة، حٌت تعتبر أمراض 
اكثر  من اٌعتبر سرطان القولون والمستقٌم واحدو. شٌوعاأمراض السرطان أكثر الامراض  والقلب 
تفٌد تقارٌر وزارة الصحة فً غزة بان سرطان  حٌث .وقطاع غزة شٌوعا فً العالم السرطانأنواع 
ٌحتل المرتبة الاولى فً السرطانات الاكثر شٌوعا بٌن مجتمع الذكور والمرتبة  القولون والمستقٌم
  . لكلا الجنسٌن بعد سرطان الثدي الثانٌة
ري معرفة مقاٌٌس معدلات البقاء على قٌد الحٌاة  لمرضى السرطان و تحلٌل محدداتها اساسً وضرو
لتقٌٌم فعالٌة النظام الصحً ككل فً التعامل مع سرطان القولون والمستقٌم من حٌث الاكتشاف 
ل العالم خاصة فً الدول المبكر، التشخٌص، والعلاج .هذه المقاٌٌس تستخدم بشكل واسع حو
 . المتقدمة
سرطان  رضىهذه الدراسة الاولى من نوعها لدراسة وتحلٌل محددات البقاء على قٌد الحٌاة لم
، على ان تساهم نتائج الدراسة فً تحسٌن فعالٌة النظام الصحً فً غزة قطاع القولون والمستقٌم فً
من خلال تقدٌم بٌانات أولٌة حول معدلات البقاء على القٌد لدى  مواجهة سرطان القولون والمستقٌم
 .المرضى
 الهدف من الدراسة
لبقاء على قٌد الحٌاة لمرضى سرطان القولون الهدف العام من هذه الدراسة هو معرفة معدلات ا
)، بالإضافة الى دراسة أهم العوامل المؤثرة 0102-8002والمستقٌم الذٌن تم تشخٌصهم خلال الفترة (
 فٌها.
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 منهجية الدراسة
-8002( الدراسة شملت جمٌع مرضى سرطان القولون والمستقٌم الذٌن تم تشخٌصهم خلال الفترة
والمسجلٌن فً المركز الوطنً لرصد الاورام وعٌادات الاورام فً مستشفٌات قطاع غزة .  )0102
 حالة لأسباب مختلفة.  17حالة بعد أن تم استناء  702العدد الاجمالً للحالات المقبولة فً الدراسة 
لتزم حصل الباحث على كافة الموافقات الادارٌة من وزارة الصحة لتسهٌل العمل فً مرافقها كما ا
حٌث الباحث بكافة المعاٌٌر الاخلاقٌة البحثٌة والامانة العلمٌة والحفاظ على سرٌة معلومات المرضى 
قام الباحث بنفسه بجمع البٌانات من ملفات المرضى وتفرٌغها  الحصول على موافقة لجنة هلسنكً.تم 
ملفات المرضى فً فً نموذج صمم مسبقا لتسهٌل عملٌة جمع البٌانات وتحلٌلها حٌث تم مراجعة 
ارشٌف عٌادة الاورام فً مستشفى د. عبد العزٌز الرنتٌسً التخصصً للأطفال، ارشٌف مستشفى 
غزة الأوروبً، الارشٌف المركزي فً مستشفى الشفاء، والارشٌف المركزي فً وزارة الصحة. تم 
ٌد الحٌاة للتحلٌل الإحصائً وتم حساب معدلات البقاء على ق 22نسخة  SSPSاستخدام برنامج 
ماٌر حٌث أظهر بان معدل البقاء على قٌد الحٌاة بعد خمس سنوات من -باستخدام طرٌقة كابلان
% هذا المعدل ٌتماشً مع النتائج المتوفرة من دول الجوار 45اكتشاف سرطان القولون بلغ 
جهة . ومن الحال فً غالبٌة الدول المتقدمة كالسعودٌة والأردن ولكنه ٌقل بشكل واضح عما هو
) بان هناك عدة عوامل لها دلالة etairavinuاظهر التحلٌل الاحصائً للمتغٌر الواحد (أخرى 
احصائٌة وهً المرض المصاحب، السمنة، التدخٌن، مرحلة المرض عند التشخٌص، النوع النسٌجً 
 xoCللورم، مكان نشأة المرض ونوعٌة العلاج. وبالرغم من ذلك اظهر التحلٌل متعدد العوامل (
دلالة احصائٌة فً التأثٌر على معدلات  لها) بان ثلاثة عوامل فقط etairavitlum-noisserger
البقاء على قٌد الحٌاة لدى مرضى السرطان القولون والمستقٌم وهً (مرحلة المرض عند التشخٌص، 
 المرض المصاحب، نوعٌة العلاج).
 اهم التوصيات:
مل للكشف المبكر عن سرطان القولون والمستقٌم توصً الدراسة بضرورة اطلاق برنامج وطنً شا
، بالإضافة الى اطلاق حملات وذوي عوامل الخطر خاصة للأشخاص فوق عمر الخمسٌن سنة
توعوٌة لزٌادة الاهتمام الرسمً والشعبً  حول مدى عبء سرطان القولون والمستقٌم ومعرفة 
من  راء دراسات اخرى تشمل عٌنة اكبرلوقاٌة منه. ومن الجٌد اجوأهم عوامل الخطر بهدف ا مسبباته
 تهتم بخدمات السرطان المقدمة فً قطاع غزة. أخرى ودراسات المرضى
